# Patent

## Title
Pyrrolidine derivatives and their use as complement pathway modulators

## Abstract

The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

## Background
This application is a U.S. National Phase filing of International Application No. PCT/IB2013/055293 filed 27 Jun. 2013, which claims priority to U.S. Application No. 61/665,468 filed 28 Jun. 2012 and 61/774,246 filed 7 Mar. 2013, the contents of which are incorporated herein by reference in their entirety.


FIELD OF THE INVENTION
The invention relates to the inhibition of the complement alternative pathway and particularly to inhibition of Factor D, in patients suffering from conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases.
BACKGROUND OF THE INVENTION
The complement system is a crucial component of the innate immunity system and comprises a group of proteins that are normally present in an inactive state. These proteins are organized in three activation pathways: the classical, the lectin, and the alternative pathways (V. M. Holers, In Clinical Immunology: Principles and Practice, ed. R. R. Rich, Mosby Press; 1996, 363-391). Molecules from microorganisms, antibodies or cellular components can activate these pathways resulting in the formation of protease complexes known as the C3-convertase and the C5-convertase. The classical pathway is a calcium/magnesium-dependent cascade, which is normally activated by the formation of antigen-antibody complexes. It can also be activated in an antibody-independent manner by the binding of C-reactive protein complexed to ligand and by many pathogens including gram-negative bacteria. The alternative pathway is a magnesium-dependent cascade which is activated by deposition and activation of C3 on certain susceptible surfaces (e.g., cell wall polysaccharides of yeast and bacteria, and certain biopolymer materials).
Factor D may be a suitable target for the inhibition of this amplification of the complement pathways because its plasma concentration in humans is very low (about 1.8 μg/mL), and it has been shown to be the limiting enzyme for activation of the alternative complement pathway (P. H. Lesavre and H. J. Müller-Eberhard. J. Exp. Med., 1978; 148: 1498-1510; J. E. Volanakis et al., New Eng. J. Med., 1985; 312:395-401).
Macular degeneration is a clinical term that is used to describe a family of diseases that are characterized by a progressive loss of central vision associated with abnormalities of Bruch's membrane, the choroid, the neural retina and/or the retinal pigment epithelium. In the center of the retina is the macula lutea, which is about 1⁄3 to 1⁄2 cm in diameter. The macula provides detailed vision, particularly in the center (the fovea), because the cones are higher in density and because of the high ratio of ganlion cells to photoreceptor cells. Blood vessels, ganglion cells, inner nuclear layer and cells, and the plexiform layers are all displaced to the side (rather than resting above the photoreceptor cells), thereby allowing light a more direct path to the cones. Under the retina is the choroid, a part of the uveal tract, and the retinal pigmented epithelium (RPE), which is between the neural retina and the choroid. The choroidal blood vessels provide nutrition to the retina and its visual cells.
Age-related macular degeneration (AMD), the most prevalent form of macular degeneration, is associated with progressive loss of visual acuity in the central portion of the visual field, changes in color vision, and abnormal dark adaptation and sensitivity. Two principal clinical manifestations of AMD have been described as the dry, or atrophic, form and the neovascular, or exudative, form. The dry form is associated with atrophic cell death of the central retina or macula, which is required for fine vision used for activities such as reading, driving or recognizing faces. About 10-20% of these AMD patients progress to the second form of AMD, known as neovascular AMD (also referred to as wet AMD).
Neovascular AMD is characterized by the abnormal growth of blood vessels under the macula and vascular leakage, resulting in displacement of the retina, hemorrhage and scarring. This results in a deterioration of sight over a period of weeks to years. Neovascular AMD cases originate from intermediate or advanced dry AMD. The neovascular form accounts for 85% of legal blindness due to AMD. In neovascular AMD, as the abnormal blood vessels leak fluid and blood, scar tissue is formed that destroys the central retina.
The new blood vessels in neovascular AMD are usually derived from the choroid and are referred to as choroidal neovascularizaton (CNV). The pathogenesis of new choroidal vessels is poorly understood, but such factors as inflammation, ischemia, and local production of angiogenic factors are thought to be important. A published study suggests that CNV is caused by complement activation in a mouse laser model (Bora P. S., J. Immunol. 2005; 174; 491-497).
Human genetic evidence implicates the involvement of the complement system, particularly the alternative pathway, in the pathogenesis of Age-related Macular Degeneration (AMD). Significant associations have been found between AMD and polymorphisms in complement factor H (CFH) (Edwards A O, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005 Apr. 15; 308(5720):421-4; Hageman G S, et al A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005 May 17; 102(20):7227-32; Haines J L, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005 Apr. 15; 308(5720):419-21; Klein R J, et al Complement factor H polymorphism in age-related macular degeneration. Science. 2005 Apr. 15; 308(5720):385-9; Lau L I, et al. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. Invest Ophthalmol Vis Sci. 2006 August; 47(8):3242-6; Simonelli F, et al. Polymorphism p. 402Y>H in the complement factor H protein is a risk factor for age related macular degeneration in an Italian population. Br J Ophthalmol. 2006 September; 90(9):1142-5; and Zareparsi S, et al Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet. 2005 July; 77(1):149-53. Complement factor B (CFB) and complement C2 (Gold B, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006 April; 38(4):458-62 and Jakobsdottir J, et al. C2 and CFB genes inage-related maculopathy and joint action with CFH and LOC387715 genes. PLoS One. 2008 May 21; 3(5):e2199), and most recently in complement C3 (Despriet D D, et al Complement component C3 and risk of age-related macular degeneration. Ophthalmology. 2009 March; 116(3):474-480.e2; Mailer J B, et al Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007 October; 39(10):1200-1 and Park K H, et al Complement component 3 (C3) haplotypes and risk of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009 July; 50(7):3386-93. Epub 2009 Feb. 21. Taken together, the genetic variations in the alternative pathway components CFH, CFB, and C3 can predict clinical outcome in nearly 80% of cases.
Currently there is no proven medical therapy for dry AMD and many patients with neovascular AMD become legally blind despite current therapy with anti-VEGF agents such as Lucentis. Thus, it would be desirable to provide therapeutic agents for the treatment or prevention of complement mediated diseases and particularly for the treatment of AMD.
SUMMARY OF THE INVENTION
The present invention provides compounds that modulate, and preferably inhibit, activation of the alternative complement pathway. In certain embodiments, the present invention provides compounds that modulate, and preferably inhibit, Factor D activity and/or Factor D mediated complement pathway activation. Such Factor D modulators are preferably high affinity Factor D inhibitors that inhibit the catalytic activity of complement Factor Ds, such as primate Factor D and particularly human Factor D.
The compounds of the present invention inhibit or suppress the amplification of the complement system caused by C3 activation irrespective of the initial mechanism of activation (including for example activation of the classical, lectin or ficolin pathways).
Various embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments.
Within certain aspects, Factor D modulators provided herein are compounds of Formula I and salts thereof:




Within certain other aspects, Factor D modulators provided herein are compounds of Formula I and salts thereof:




In another embodiment, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound according to the definition of formula (I) or formula (II) or subformulae thereof and one or more pharmaceutically acceptable carriers.
In another embodiment, the invention provides a combination, in particular a pharmaceutical combination, comprising a therapeutically effective amount of the compound according to the definition of formula (I) or formula (II) or subformulae thereof and one or more therapeutically active.
The invention further provides methods of treating or preventing complement mediated diseases, the method comprising the steps of identifying a patient in need of complement modulation therapy and administering a compound of Formula (I) or formula (II) or a subformulae thereof. Complement mediated diseases include ophthalmic diseases (including early or neovascular age-related macular degeneration and geographic atrophy), autoimmune diseases (including arthritis, rheumatoid arthritis), respiratory diseases, cardiovascular diseases.
Other aspects of the invention are discussed infra.


DETAILED DESCRIPTION OF THE INVENTION
As noted above, the present invention provides compounds that modulate Factor D activation and/or Factor D-mediated signal transduction of the complement system. Such compounds may be used in vitro or in vivo to modulate (preferably inhibit) Factor D activity in a variety of contexts.
In a first embodiment, the invention provides compounds of Formula I and pharmaceutically acceptable salts thereof, which modulate the alternative pathway of the complement system. Compounds of Formula I are represented by the structure:




Wherein
A is a group selected from:




Z1 is C(R1) or N;
Z2 is C(R2) or N;
Z3 is C(R3) or N, wherein at least one of Z1, Z2 or Z3 is not N;
R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6alkoxy, haloC-C6alkyl, haloC-C6alkoxy C1-C6alkoxycarbonyl, CO2H and C(O)NRARB;
R2 and R3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, NRCRD, cyano, CO2H, CONRARB, SO2C1-C6alkyl, and SO2NH2, SO2NRARB, C1-C6alkoxycarbonyl, —C(NRA)NRCRD, C1-C6alkyl, haloC1-C6alkyl, C2-C6alkenyl, C1-C6alkoxy, haloC1-C6alkoxy, C2-C6alkenyloxy, wherein each alkyl, alkenyl, alkoxy and alkenyloxy is unsubstituted or substituted with up to 4 substitutents independently selected from halogen, hydroxy, cyano, tetrazole, C1-C4alkoxy, C1-C4haloalkoxy, CO2H, C1-C6alkoxycarbonyl, C(O)NRARB, NRCRD, optionally substituted phenyl, heterocycle having 4 to 7 ring atoms and 1, 2, or 3 ring heteroatoms selected from N, O or S, optionally substituted heteroaryl having 5 or 6 ring atoms and 1 or 2 or 3 ring heteroatoms selected from N, O or S, and wherein optional phenyl and heteroaryl substituents are selected from halogen, hydroxy, C1-C4alkyl, C1-C4alkoxy and CO2H;
R4 is selected from the group consisting of hydrogen, halogen, and C1-C6alkyl;
R5 is C1-C4alkyl, hydroxyC1-C4alkyl, C1-C4alkoxyC1-C4alkyl, haloC1-C4alkyl, amino, methylamino;
X1 is CR9R22 or sulfur;
X2 is CR7R8, oxygen, sulfur, N(H) or N(C1-C6alkyl), wherein at least one of X1 and X2 is carbon; or
X1 and X2, in combination, forms an olefin of the formula —C(R7)═C(H)— or —C(R7)═C(C1-C4alkyl)-, wherein the C(R7) is attached to X3;
X3 is (CR6R21)q or N(H) wherein q is 0, 1 or 2, wherein X3 is CR6R21 or (CR6R21)2 when either X1 or X2 is sulfur or X2 is oxygen; or
X2 and X3, taken in combination, are —N═C(H)— or —N═C(C1-C4alkyl)- in which the C(H) or C(C1-C4alkyl) is attached to X1;
R6 is selected from the group consisting of hydrogen and C1-C6alkyl;
R7 is hydrogen, halogen, hydroxy, cyano, C1-C6alkyl, C1-C6alkoxy, hydroxyC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, haloC1-C6alkyl, or C1-C6haloalkoxy;
R8 is hydrogen, halogen, hydroxy, azide, cyano, COOH, C1-C6alkoxycarbonyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, NRARB, N(H)C(O)C1-C6alkyl, hydroxyC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or C1-C6alkyl substituted with NRARB, N(H)C(O)H or N(H)C(O)(C1-C4alkyl);
R9 is selected from the group consisting of hydrogen, hydroxy, halogen, C1-C6alkyl, haloC1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxy, haloC1-C6alkoxy, NRARB, N(H)C(O)C1-C6alkyl, N(H)C(O)OC1-C6alkyl and OC(O)NRCRD each of alkyl, alkoxy, alkenyl, and alkynyl substituents may be substituted with 0, 1, or 2 groups independently selected at each occurrence from the group consisting of halogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, and NRARB;
R20 is hydrogen or C1-C6alkyl;
R21 is selected from the group consisting of hydrogen, phenyl and C1-C6alkyl, which alkyl group is unsubstituted or substituted with hydroxy, amino, azide, and NHC(O)C1-C6alkyl;
R22 is selected from the group consisting of hydrogen, halogen, hydroxy, amino and C1-C6alkyl;
CR7R8, taken in combination forms a spirocyclic 3 to 6 membered carbocycle which is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen and methyl; or
R7 and R8, taken in combination, form an exocyclic methylidene (═CH2);
R7 and R22 or R8 and R9, taken in combination form an epoxide ring or a 3 to 6 membered carbocyclic ring system which carbocyclic ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, methyl, ethyl, hydroxyC1-C4alkyl, C1-C6alkoxyC1-C4alkyl, C1-C4alkoxycarbonyl, CO2H, and C1-C4alkyl substituted with NRARB;
R6 and R7 or R8 and R21, taken in combination, form a fused 3 membered carbocyclic ring system which is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, methyl, ethyl, hydroxyC1-C4alkyl, C1-C6alkoxyC1-C4alkyl, C1-C4alkoxycarbonyl, CO2H, and C1-C4alkyl substituted with NRARB; or
R20 and R22 taken in combination form a fused 3 carbocyclic ring system;
R9 and R21 taken in combination form a form 1 to 3 carbon alkylene linker;
R7 and R29 taken in combination form 1 to 3 carbon alkylene linker;
R19 and R11 are independently selected from hydrogen, halogen, C1-C4alkyl, hydroxyC1-C6alkyl, C1-C4alkoxyC1-C4alkyl and haloC1-C4alkyl; or
R19 and R11 taken together can form a 3 to 6 carbocycle or heterocycle containing 1 heteroatom O or S optionally substituted with 1 or 2 groups independently selected from hydroxyl, halogen C1-C4alkyl and C1-C4alkoxy;
R12 is hydrogen C1-C4alkyl, haloC1-C4alkyl, hydroxyC1-C4alkyl or C1-C4alkoxyC1-C4alkyl;
RA and RB are independently selected from the group consisting of hydrogen, and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, hydroxyC1-C6alkyl, or NRARB, taken in combination, form a heterocycle having 4 to 7 ring atoms and 0 or 1 additional ring N, O or S atoms, which heterocycle is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-C4alkyl, halogen, hydroxy, C1-C4alkoxy; and
RC and RD, are each independently selected from the group consisting of hydrogen and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or hydroxyC1-C6alkyl.
In a second embodiment, the invention provides compounds of Formula II and pharmaceutically acceptable salts thereof, which modulate the alternative pathway of the complement system. Compounds of Formula II are represented by the structure:




wherein
A is a group selected from:




Z1 is C(R1) or N;
Z2 is C(R2) or N;
Z3 is C(R3) or N, wherein at least one of Z1, Z2 or Z3 is not N;
R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6alkoxy, haloC-C6alkyl, haloC-C6alkoxy, C1-C6alkoxycarbonyl, CO2H and C(O)NRARB;
R2 and R3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, NRCRD, cyano, CO2H, CONRARB, SO2C1-C6alkyl, and SO2NH2, SO2NRARB, C1-C6alkoxycarbonyl, —C(NRA)NRCRD, C1-C6alkyl, haloC1-C6alkyl, C2-C6alkenyl, C1-C6alkoxy, haloC1-C6alkoxy, C2-C6alkenyloxy, wherein each alkyl, alkenyl, alkoxy and alkenyloxy is unsubstituted or substituted with up to 4 substitutents independently selected from halogen, hydroxy, cyano, tetrazole, C1-C4alkoxy, C1-C4haloalkoxy, CO2H, C1-C6alkoxycarbonyl, C(O)NRARB, NRCRD, optionally substituted phenyl, heterocycle having 4 to 7 ring atoms and 1, 2, or 3 ring heteroatoms selected from N, O or S, optionally substituted heteroaryl having 5 or 6 ring atoms and 1 or 2 or 3 ring heteroatoms selected from N, O or S, and wherein optional phenyl and heteroaryl substituents are selected from halogen, hydroxy, C1-C4alkyl, C1-C4alkoxy and CO2H;
R4 is selected from the group consisting of hydrogen, halogen, and C1-C6alkyl;
R5 is C1-C4alkyl, hydroxyC1-C4alkyl, C1-C4alkoxyC1-C4alkyl, haloC1-C4alkyl, amino, methylamino
R6 is hydrogen;
R7 is hydrogen or fluoro;
R9 is hydrogen, methyl or hydroxymethyl;
R9 is hydrogen, halogen, hydroxy or methoxy; or
R6 and R7, taken in combination, form a cyclopropane ring; or
R8 and R9, taken in combination, form a cyclopropane ring;
R10 and R11 are independently selected from hydrogen, halogen, C1-C4alkyl, hydroxyC1-C4alkyl, C1-C4alkoxyC1-C4alkyl and haloC1-C4alkyl; or
R10 and R11 taken together can form a 3 to 6 carbocycle or heterocycle containing 1 heteroatom O or S optionally substituted with 1 or 2 groups independently selected from hydroxyl, halogen C1-C4alkyl and C1-C4alkoxy;
R12 is hydrogen C1-C4alkyl, haloC1-C4alkyl, hydroxyC1-C4alkyl or C1-C4alkoxyC1-C4alkyl;
RA and RB are independently selected from the group consisting of hydrogen, and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, hydroxyC1-C6alkyl, or NRARB, taken in combination, form a heterocycle having 4 to 7 ring atoms and 0 or 1 additional ring N, O or S atoms, which heterocycle is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-C4alkyl, halogen, hydroxy, C1-C4alkoxy; and
RC and RD, are each independently selected from the group consisting of hydrogen and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or hydroxyC1-C6alkyl.
In a third embodiment, compounds, or salts thereof, according to embodiment one or two are provided. Compounds of the third embodiment are represented by Formula III or Formula IV:




In a fourth embodiment, a compound or salt thereof according to any one of embodiments one to three is provided in which at least two of Z1, Z2 and Z3 are not N.
In a fifth embodiment, a compound or salt thereof according to any one of embodiments one to four is provided in which Z3 is CR3;
R1 is hydrogen, halogen or C1-C4alkyl;
R2 and R3 are independently selected from the group consisting of hydrogen, halogen, CO2H, C1-C4alkyl and C1-C4alkoxy; wherein alkoxy is unsubstituted or substituted with optionally substituted heteroaryl having 5 or 6 ring atoms and 1, 2 or 3 ring heteroatoms selected from N, O or S, and wherein the heteroaryl is optionally substituted with 1 or 2 halogen or C1-C4alkyl groups;
R4 is hydrogen; and
R5 is amino or C1-C4alkyl.
In a sixth embodiment, a compound or salt thereof according to any one of embodiments one to five is provided in which R6 and R7 taken in combination form a cyclopropane ring;
R8 is hydrogen, methyl or hydroxymethyl; and
R9 is hydrogen.
In a seventh embodiment, a compound or salt thereof according to any one of embodiments one to five is provided in which R6 and R7 are hydrogen; and
R8 and R9 taken in combination form a cyclopropane ring;
In an eighth embodiment, a compound or salt thereof according to any one of embodiments one to five is provided in which R6 and R8 are hydrogen;
R7 is fluoro; and
R9 is hydrogen or methoxy.
In a ninth embodiment, a compound or salt thereof according to any one of embodiments one to eight is provided in which R10 and R11 are methyl.
In a tenth embodiment, a compound or salt thereof according to any one of embodiments one to nine is provided in which R12 is hydrogen
In an eleventh embodiment, a compound or salt thereof according to any one of embodiments one to nine is provided in which R12 is methyl.
In a twelfth embodiment, a compound or salt thereof according to any one of embodiments one or two is provided in which the compound is selected from the group consisting of

    6-Chloro-1-{2-[(1R,3S,5R)-3-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-thyl}-1H-indazole-3-carboxylic acid amide;
    1-{2-[(2S,4R)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-6-methyl-1H-indazole-3-carboxylic acid amide;
    1-{2-[(2S,3S,4S)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-3-methoxy-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
    1-{2-[(1R,3S,5S)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-5-hydroxymethyl-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
    1-{2-[(2S,4R)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
    1-{2-[(2S,3S,4S)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-3-methoxy-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-5,7-dimethyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
    (1R,3S,5R)-2-[2-(3-Acetyl-indazol-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-5-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
    (1R,3S,5R)-2-[2-(3-Acetyl-pyrazolo[3,4-c]pyridin-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-7-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
    5-Ethyl-1-{2-[(1R,3S,5R)-3-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
    (1R,3S,5R)-2-{2-[3-Acetyl-5-(pyrimidin-2-ylmethoxy)-indazol-1-yl]-acetyl}-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide;
    1-{2-[(1R,3S,5R)-3-(2-Cyclopentylidene-2-fluoro-ethylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-di-(trideutero-methyl)-allylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
    1-{2-[(1R,3S,5R)-3-(2-Fluoro-1,3-dimethyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide; and
    (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide]3-[(2-fluoro-3-methyl-but-2-enyl)-amide]
    1-(2-oxo-2-((1R,3S,5R)-3-(((Z)-2,4,4,4-tetrafluorobut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)ethyl)-1H-indazole-3-carboxamide
    1-(2-((1R,3S,5R)-3-((S)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide
    1-(2-((1R,3S,5R)-3-((R)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide.


Some of the compounds listed supra have been prepared in enantiopure form (i.e., greater than about 80%, greater than 90% or greater than 95% enantiomeric purity). Other compounds have been isolated as mixtures of stereoisomers, e.g., diastereoisomeric mixtures of two or more diastereoisomers. Each compound isolated as a mixture of stereoisomers has been marked as mixture in the foregoing list.
In one embodiment, the invention provides a combination, in particular a pharmaceutical combination, comprising a therapeutically effective amount of the compound according to the definition of formula (I), (II), (III), (IV) or subformulae thereof or any one of the specifically disclosed compounds of the invention and one or more therapeutically active agents (preferably selected from those listed infra).
For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.
As used herein, the term “alkyl” refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 20 carbon atoms. Unless otherwise provided, alkyl refers to hydrocarbon moieties having 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
As used herein, the term “alkylene” refers to divalent alkyl group as defined herein above having 1 to 20 carbon atoms. It comprises 1 to 20 carbon atoms, Unless otherwise provided, alkylene refers to moieties having 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms. Representative examples of alkylene include, but are not limited to, methylene, ethylene, n-propylene, iso-propylene, n-butylene, sec-butylene, iso-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, n-hexylene, 3-methylhexylene, 2,2-dimethylpentylene, 2,3-dimethylpentylene, n-heptylene, n-octylene, n-nonylene, n-decylene and the like.
As used herein, the term “haloalkyl” refers to an alkyl as defined herein, that is substituted by one or more halo groups as defined herein. The haloalkyl can be monohaloalkyl, dihaloalkyl or polyhaloalkyl including perhaloalkyl. A monohaloalkyl can have one iodo, bromo, chloro or fluoro within the alkyl group. Dihaloalky and polyhaloalkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl. Typically the polyhaloalkyl contains up to 12, or 10, or 8, or 6, or 4, or 3, or 2 halo groups. Non-limiting examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. A perhaloalkyl refers to an alkyl having all hydrogen atoms replaced with halo atoms.
The term “aryl” refers to an aromatic hydrocarbon group having 6-20 carbon atoms in the ring portion. Typically, aryl is monocyclic, bicyclic or tricyclic aryl having 6-20 carbon atoms.
Furthermore, the term “aryl” as used herein, refers to an aromatic substituent which can be a single aromatic ring, or multiple aromatic rings that are fused together.
Non-limiting examples include phenyl, naphthyl or tetrahydronaphthyl, each of which may optionally be substituted by 1-4 substituents, such as alkyl, trifluoromethyl, cycloalkyl, halogen, hydroxy, alkoxy, acyl, alkyl-C(O)—O—, aryl-O—, heteroaryl-O—, amino, thiol, alkyl-S—, aryl-S—, nitro, cyano, carboxy, alkyl-O—C(O)—, carbamoyl, alkyl-S(O)—, sulfonyl, sulfonamido, phenyl, and heterocyclyl.
As used herein, the term “alkoxy” refers to alkyl-O—, wherein alkyl is defined herein above. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- and the like. Typically, alkoxy groups have about 1-7, more preferably about 1-4 carbons.
As used herein, the term “heterocyclyl” or “heterocyclo” refers to a saturated or unsaturated non-aromatic ring or ring system, e.g., which is a 4-, 5-, 6-, or 7-membered monocyclic, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic or 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic ring system and contains at least one heteroatom selected from O, S and N, where the N and S can also optionally be oxidized to various oxidation states. The heterocyclic group can be attached at a heteroatom or a carbon atom. The heterocyclyl can include fused or bridged rings as well as spirocyclic rings. Examples of heterocycles include tetrahydrofuran (THF), dihydrofuran, 1,4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane, thiomorpholine, and the like.
The term “heterocyclyl” further refers to heterocyclic groups as defined herein substituted with 1 to 5 substituents independently selected from the groups consisting of the following:
(a) alkyl;
(b) hydroxy (or protected hydroxy);
(c) halo;
(d) oxo, i.e., ═O;
(e) amino, alkylamino or dialkylamino;
(f) alkoxy;
(g) cycloalkyl;
(h) carboxyl;
(i) heterocyclooxy, wherein heterocyclooxy denotes a heterocyclic group bonded through an oxygen bridge;
(j) alkyl-O—C(O)—;
(k) mercapto;
(l) nitro;
(m) cyano;
(n) sulfamoyl or sulfonamido;
(o) aryl;
(p) alkyl-C(O)—O—;
(q) aryl-C(O)—O—;
(r) aryl-S—;
(s) aryloxy;
(t) alkyl-S—;
(u) formyl, i.e., HC(O)—;
(v) carbamoyl;
(w) aryl-alkyl-; and
(x) aryl substituted with alkyl, cycloalkyl, alkoxy, hydroxy, amino, alkyl-C(O)—NH—, alkylamino, dialkylamino or halogen.
As used herein, the term “cycloalkyl” refers to saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon groups of 3-12 carbon atoms. Unless otherwise provided, cycloalkyl refers to cyclic hydrocarbon groups having between 3 and 9 ring carbon atoms or between 3 and 7 ring carbon atoms, each of which can be optionally substituted by one, or two, or three, or more substituents independently selected from the group consisting of alkyl, halo, oxo, hydroxy, alkoxy, alkyl-C(O)—, acylamino, carbamoyl, alkyl-NH—, (alkyl)2N—, thiol, alkyl-S—, nitro, cyano, carboxy, alkyl-O—C(O)—, sulfonyl, sulfonamido, sulfamoyl, and heterocyclyl. Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl and the like. Exemplary bicyclic hydrocarbon groups include bornyl, indyl, hexahydroindyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl and the like. Exemplary tricyclic hydrocarbon groups include adamantyl and the like.
As used herein, the term “aryloxy” refers to both an —O-aryl and an —O-heteroaryl group, wherein aryl and heteroaryl are defined herein.
As used herein, the term “heteroaryl” refers to a 5-14 membered monocyclic- or bicyclic- or tricyclic-aromatic ring system, having 1 to 8 heteroatoms selected from N, O or S. Typically, the heteroaryl is a 5-10 membered ring system (e.g., 5-7 membered monocycle or an 8-10 membered bicycle) or a 5-7 membered ring system. Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, and 2-, 4-, or 5-pyrimidinyl.
The term “heteroaryl” also refers to a group in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoliyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinoliyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-, 3-, 4-, 5-, or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-4aH carhazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-carbzaolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-perimidinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10-phenathrolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenoxazinyl, 2-, 3-, 4-, 5-, 6-, or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-benzisoqinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanyl, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-7H-pyrazino[2,3-c]carbazolyl, 2-, 3-, 5-, 6-, or 7-2H-furo[3,2-b]-pyranyl, 2-, 3-, 4-, 5-, 7-, or 8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3-, or 5-1H-pyrazolo[4,3-d]-oxazolyl, 2-, 4-, or 54H-imidazo[4,5-d]thiazolyl, 3-, 5-, or 8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5-, or 6-imidazo[2,1-b]thiazolyl, 1-, 3-, 6-, 7-, 8-, or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10, or 11-4H- pyrido[2,3-c]carbazolyl, 2-, 3-, 6-, or 7-imidazo[1,2-b][1,2,4]triazinyl, 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-, or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-1H-pyrrolo[1,2-b][2]benzazapinyl. Typical fused heteroary groups include, but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, and 2-, 4-, 5-, 6-, or 7-benzothiazolyl.
A heteroaryl group may be substituted with 1 to 5 substituents independently selected from the groups consisting of the following:
(a) alkyl;
(b) hydroxy (or protected hydroxy);
(c) halo;
(d) oxo, i.e., ═O;
(e) amino, alkylamino or dialkylamino;
(f) alkoxy;
(g) cycloalkyl;
(h) carboxyl;
(i) heterocyclooxy, wherein heterocyclooxy denotes a heterocyclic group bonded through an oxygen bridge;
(j) alkyl-O—C(O)—;
(k) mercapto;
(l) nitro;
(m) cyano;
(n) sulfamoyl or sulfonamido;
(o) aryl;
(p) alkyl-C(O)—O—;
(q) aryl-C(O)—O—;
(r) aryl-S—;
(s) aryloxy;
(t) alkyl-S—;
(u) formyl, i.e., HC(O)—;
(v) carbamoyl;
(w) aryl-alkyl-; and
(x) aryl substituted with alkyl, cycloalkyl, alkoxy, hydroxy, amino, alkyl-C(O)—NH—, alkylamino, dialkylamino or halogen.
As used herein, the term “halogen” or “halo” refers to fluoro, chloro, bromo, and iodo.
As used herein, the term “optionally substituted” unless otherwise specified refers to a group that is unsubstituted or is substituted by one or more, typically 1, 2, 3 or 4, suitable non-hydrogen substituents, each of which is independently selected from the group consisting of:
(a) alkyl;
(b) hydroxy (or protected hydroxy);
(c) halo;
(d) oxo, i.e., ═O;
(e) amino, alkylamino or dialkylamino;
(f) alkoxy;
(g) cycloalkyl;
(h) carboxyl;
(i) heterocyclooxy, wherein heterocyclooxy denotes a heterocyclic group bonded through an oxygen bridge;
(j) alkyl-O—C(O)—;
(k) mercapto;
(l) nitro;
(m) cyano;
(n) sulfamoyl or sulfonamido;
(o) aryl;
(p) alkyl-C(O)—O—;
(q) aryl-C(O)—O—;
(r) aryl-S—;
(s) aryloxy;
(t) alkyl-S—;
(u) formyl, i.e., HC(O)—;
(v) carbamoyl;
(w) aryl-alkyl-; and
(x) aryl substituted with alkyl, cycloalkyl, alkoxy, hydroxy, amino, alkyl-C(O)—NH—, alkylamino, dialkylamino or halogen.
As used herein, the term “isomers” refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms. Also as used herein, the term “an optical isomer” or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term is used to designate a racemic mixture where appropriate. The asterisk (*) indicated in the name of a compound designate a racemic mixture. “Diastereoisomers” or “diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (−) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
As used herein, the term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfornate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate and trifluoroacetate salts. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
The pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in “Remington's Pharmaceutical Sciences”, 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35S, 36Cl, 125I respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H, 13C, and 14C, are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term “isotopic enrichment factor” as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
In certain embodiments, selective deuteration of compounds of Formula (I) or formula (II) include deuteration of R5, when R5 is alkanoyl, e.g., C(O)CD3. In other embodiments, certain substitutents on the proline ring are selectively deuterated. For example, when any of R8 or R9 are methyl or methoxy, the alkyl residue is preferably deuterated, e.g., CD3 or OCD3. In certain other compounds, when two substituents of the proline ring are combined to form a cyclopropyl ring, the unsubstituted methylene carbon is selectively deuterated. In certain other compounds of Formulae (I), (II), (III) or (IV), R10, R11 and/or R12 is deuterated alkyl, preferably CD3.
Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
The compounds of the present invention may inherently or by design form solvates with solvents (including water). Therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term “solvate” refers to a molecular complex of a compound of the present invention (including salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to a recipient, e.g., water, ethanol, dimethylsulfoxide, acetone and other common organic solvents. The term “hydrate” refers to a molecular complex comprising a compound of the invention and water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMSO.
Compounds of the invention, i.e. compounds of formula (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (I).
As used herein, the term “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
The term “a therapeutically effective amount” of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder, or a disease or biological process (e.g., tissue regeneration and reproduction) (i) mediated by Factor D, or (ii) associated with Factor D activity, or (iii) characterized by activity (normal or abnormal) of the complement alternative pathway; or (2) reducing or inhibiting the activity of Factor D; or (3) reducing or inhibiting the expression of Factor D; or (4) reducing or inhibiting activation of the complement system and particularly reducing or inhibiting generation of C3a, iC3b, C5a or the membrane attack complex generated by activation of the complement alternative pathway. In another non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of Factor D and/or the complement alternative pathway; or at least partially reducing or inhibiting the expression of Factor D and/or the complement alternative pathway. The meaning of the term “a therapeutically effective amount” as illustrated in the above embodiment for Factor D and/or the complement alternative pathway.
As used herein, the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
As used herein, the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
As used herein, the term “a,” “an,” “the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)-configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)-configuration. Substituents at atoms with unsaturated bonds may, if possible, be present in cis-(Z)- or trans-(E)-form.
Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Compounds of the present invention are either obtained in the free form, as a salt thereof, or as prodrug derivatives thereof.
When both a basic group and an acid group are present in the same molecule, the compounds of the present invention may also form internal salts, e.g., zwitterionic molecules.
The present invention also provides pro-drugs of the compounds of the present invention that converts in vivo to the compounds of the present invention. A pro-drug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a subject. The suitability and techniques involved in making and using pro-drugs are well known by those skilled in the art. Prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. See The Practice of Medicinal Chemistry, Ch. 31-32 (Ed. Wermuth, Academic Press, San Diego, Calif., 2001). Generally, bioprecursor prodrugs are compounds, which are inactive or have low activity compared to the corresponding active drug compound, that contain one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity.
Carrier prodrugs are drug compounds that contain a transport moiety, e.g., that improve uptake and/or localized delivery to a site(s) of action. Desirably for such a carrier prodrug, the linkage between the drug moiety and the transport moiety is a covalent bond, the prodrug is inactive or less active than the drug compound, and any released transport moiety is acceptably non-toxic. For prodrugs where the transport moiety is intended to enhance uptake, typically the release of the transport moiety should be rapid. In other cases, it is desirable to utilize a moiety that provides slow release, e.g., certain polymers or other moieties, such as cyclodextrins. Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, and/or improvement in drug formulation (e.g., stability, water solubility, suppression of an undesirable organoleptic or physiochemical property). For example, lipophilicity can be increased by esterification of (a) hydroxyl groups with lipophilic carboxylic acids (e.g., a carboxylic acid having at least one lipophilic moiety), or (b) carboxylic acid groups with lipophilic alcohols (e.g., an alcohol having at least one lipophilic moiety, for example aliphatic alcohols).
Exemplary prodrugs are, e.g., esters of free carboxylic acids and S-acyl derivatives of thiols and O-acyl derivatives of alcohols or phenols, wherein acyl has a meaning as defined herein. Suitable prodrugs are often pharmaceutically acceptable ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di-substituted lower alkyl esters, such as the ω-(amino, mono- or di-lower alkylamino, carboxy, lower alkoxycarbonyl)-lower alkyl esters, the α-(lower alkanoyloxy, lower alkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, such as the pivaloyloxymethyl ester and the like conventionally used in the art. In addition, amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bundgaard, J. Med. Chem. 2503 (1989)). Moreover, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard, Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
Within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention is designated a “protecting group”, unless the context indicates otherwise. The protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as J. F. W. McOmie, “Protective Groups in Organic Chemistry”, Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, in “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in “Methoden der organischen Chemie” (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jeschkeit, “Aminosäuren, Peptide, Proteine” (Amino acids, Peptides, Proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide and Derivate” (Chemistry of Carbohydrates: Monosaccharides and Derivatives), Georg Thieme Verlag, Stuttgart 1974. A characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g. by enzymatic cleavage).
Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known to those skilled in the art. For example, salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used. Acid addition salts of compounds of the present invention are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange reagent. Internal salts of compounds of the present invention containing acid and basic salt-forming groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers.
Salts can be converted into the free compounds in accordance with methods known to those skilled in the art. Metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent.
Mixtures of isomers obtainable according to the invention can be separated in a manner known to those skilled in the art into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
The following applies in general to all processes mentioned herein before and hereinafter.
All the above-mentioned process steps can be carried out under reaction conditions that are known to those skilled in the art, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, including, for example, solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g. in the H+ form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, for example in a temperature range of from about −100° C. to about 190° C., including, for example, from approximately −80° C. to approximately 150° C., for example at from −80 to −60° C., at room temperature, at from −20 to 40° C. or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under an argon or nitrogen atmosphere.
At all stages of the reactions, mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers, for example analogously to the methods described under “Additional process steps”.
The solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride, cyclic, linear or branched hydrocarbons, such as cyclohexane, hexane or isopentane, methycyclohexane, or mixtures of those solvents, for example aqueous solutions, unless otherwise indicated in the description of the processes. Such solvent mixtures may also be used in working up, for example by chromatography or partitioning.
The compounds, including their salts, may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
The invention relates also to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts utilized to synthesize the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21).
Typically, the compounds of formula (I) can be prepared according to the Schemes provided infra.
A compound of the formula IV or V can, for example, be prepared from a corresponding N-protected amino acid as described below:




By reacting an N-protected amino acid I wherein PG is a protecting group or a reactive derivative thereof with an amino compound, under condensation conditions to obtain a compound of the formula II. Removing the protecting group and reacting the compound of the formula III with an isocyanate to obtain a compound of the formula IV or with an acid or a reactive derivative thereof under condensation conditions to obtain a compound of the formula V.
The invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure materials.
Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art.
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and ophthalmic administration, etc. In addition, the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions, emulsions, each of which may be suitable for ophthalmic administration). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifers and buffers, etc.
Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with

    
    
        a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
        b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also
        c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired
        d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or
        e) absorbents, colorants, flavors and sweeteners.
    
    


Tablets may be either film coated or enteric coated according to methods known in the art.
Suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
Suitable compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for ophthalmic application, e.g., for the treatment of eye diseases e.g., for therapeutic or prophylactic use in treating age related macular degeneration and other complement mediated ophthalmic disorders. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be desirable.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
The present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
The invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
Prophylactic and Therapeutic Uses
The compounds of formula I in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g. Factor D modulating properties, complement pathway modulating properties and modulation of the complement alternative pathway properties, e.g. as indicated in in vitro and in vivo tests as provided in the next sections and are therefore indicated for therapy.
The present invention provides methods of treating a disease or disorder associated with increased complement activity by administering to a subject in need thereof an effective amount of the compounds of Formula (I) of the invention. In certain aspects, methods are provided for the treatment of diseases associated with increased activity of the C3 amplification loop of the complement pathway. In certain embodiments, methods of treating or preventing complement mediated diseases are provided in which the complement activation is induced by antibody-antigen interactions, by a component of an autoimmune disease, or by ischemic damage.
In a specific embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of the compound of Formula (I) of the invention. In certain embodiments, patients who are currently asymptomatic but are at risk of developing a symptomatic macular degeneration related disorder are suitable for administration with a compound of the invention. The methods of treating or preventing AMD include, but are not limited to, methods of treating or preventing one or more symptoms or aspects of AMD selected from formation of ocular drusen, inflammation of the eye or eye tissue, loss of photoreceptor cells, loss of vision (including loss of visual acuity or visual field), neovascularization (including CNV), retinal detachment, photoreceptor degeneration, RPE degeneration, retinal degeneration, chorioretinal degeneration, cone degeneration, retinal dysfunction, retinal damage in response to light exposure, damage of the Bruch's membrane, and/or loss of RPE function.
The compound of Formula (I) of the invention can be used, inter alia, to prevent the onset of AMD, to prevent the progression of early AMD to advanced forms of AMD including neovascular AMD or geographic atrophy, to slow and/or prevent progression of geographic atrophy, to treat or prevent macular edema from AMD or other conditions (such as diabetic retinopathy, uveitis, or post surgical or non-surgical trauma), to prevent or reduce the loss of vision from AMD, and to improve vision lost due to pre-existing early or advanced AMD. It can also be used in combination with anti-VEGF therapies for the treatment of neovascular AMD patients or for the prevention of neovascular AMD. The present invention further provides methods of treating a complement related disease or disorder by administering to a subject in need thereof an effective amount of the compound(s) of the invention, wherein said disease or disorder is selected from uveitis, adult macuar degeneration, diabetic retinopathy, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, imtermediate uveitis, birdshot retino-chorioditis, sympathetic ophthalmia, ocular dicatricial pemphigoid, ocular pemphigus, nonartertic ischemic optic neuropathy, post-operative inflammation, and retinal vein occlusion.
In some embodiments, the present invention provides methods of treating a complement related disease or disorder by administering to a subject in need thereof an effective amount of the compounds of the invention. Examples of known complement related diseases or disorders include: neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, thermal injury including burns or frostbite, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration and neural regeneration. In addition, other known complement related disease are lung disease and disorders such as dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, inert dusts and minerals (e.g., silicon, coal dust, beryllium, and asbestos), pulmonary fibrosis, organic dust diseases, chemical injury (due to irritant gases and chemicals, e.g., chlorine, phosgene, sulfur dioxide, hydrogen sulfide, nitrogen dioxide, ammonia, and hydrochloric acid), smoke injury, thermal injury (e.g., burn, freeze), asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, uveitis (including Behcet's disease and other sub-types of uveitis), antiphospholipid syndrome.
In a specific embodiment, the present invention provides methods of treating a complement related disease or disorder by administering to a subject in need thereof an effective amount of the compounds of the invention, wherein said disease or disorder is asthma, arthritis (e.g., rheumatoid arthritis), autoimmune heart disease, multiple sclerosis, inflammatory bowel disease, ischemia-reperfusion injuries, Barraquer-Simons Syndrome, hemodialysis, anca vasculitis, cryoglobulinemia, systemic lupus, lupus erythematosus, psoriasis, multiple sclerosis, transplantation, diseases of the central nervous system such as Alzheimer's disease and other neurodegenerative conditions, atypicaly hemolytic uremic syndrome (aHUS), glomerulonephritis (including membrane proliferative glomerulonephritis), dense deposit disease, blistering cutaneous diseases (including bullous pemphigoid, pemphigus, and epidermolysis bullosa), ocular cicatrical pemphigoid or MPGN II.
In a specific embodiment, the present invention provides methods of treating glomerulonephritis by administering to a subject in need thereof an effective amount of a composition comprising a compound of the present invention. Symptoms of glomerulonephritis include, but not limited to, proteinuria; reduced glomerular filtration rate (GFR); serum electrolyte changes including azotemia (uremia, excessive blood urea nitrogen—BUN) and salt retention, leading to water retention resulting in hypertension and edema; hematuria and abnormal urinary sediments including red cell casts; hypoalbuminemia; hyperlipidemia; and lipiduria. In a specific embodiment, the present invention provides methods of treating paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of a composition comprising an compound of the present invention with or without concomitent administration of a complement C5 inhibitor or C5 convertase inhibitor such as Soliris.
In a specific embodiment, the present invention provides methods of reducing the dysfunction of the immune and/or hemostatic systems associated with extracorporeal circulation by administering to a subject in need thereof an effective amount of a composition comprising an compound of the present invention. The compounds of the present invention can be used in any procedure which involves circulating the patient's blood from a blood vessel of the patient, through a conduit, and back to a blood vessel of the patient, the conduit having a luminal surface comprising a material capable of causing at least one of complement activation, platelet activation, leukocyte activation, or platelet-leukocyte adhesion. Such procedures include, but are not limited to, all forms of ECC, as well as procedures involving the introduction of an artificial or foreign organ, tissue, or vessel into the blood circuit of a patient. More particularly, such procedures include, but are not limited to, transplantation procedures including kidney, liver, lung or heart transplant procedures and islet cell transplant procedures.
In other embodiments, the compounds of the invention are suitable for use in the treatment of diseases and disorders associated with fatty acid metabolism, including obesity and other metabolic disorders.
In another embodiment, the compounds of the invention may be used in blood ampules, diagnostic kits and other equipment used in the collection and sampling of blood. The use of the compounds of the invention in such diagnostic kits may inhibit the ex vivo activation of the complement pathway associated with blood sampling.
The pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage in vitro may range between about 10−3 molar and 10−9 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.
The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods.
The compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
In one embodiment, the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition mediated by alternative complement pathway. Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.
In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.
In the combination therapies of the invention, the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
Accordingly, the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by the complement alternative pathway, wherein the medicament is prepared for administration with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by the complement alternative pathway, wherein the medicament is administered with a compound of formula (I).
The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by the complement alternative pathway, wherein the compound of formula (I) is prepared for administration with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by the complement alternative pathway and/or Factor D, wherein the other therapeutic agent is prepared for administration with a compound of formula (I). The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by the complement alternative pathway and/or Factor D, wherein the compound of formula (I) is administered with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by the complement alternative pathway and/or Factor D, wherein the other therapeutic agent is administered with a compound of formula (I).
The invention also provides the use of a compound of formula (I) for treating a disease or condition mediated by the complement alternative pathway and/or Factor D, wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by the complement alternative pathway and/or Factor D wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I).
The pharmaceutical compositions can be administered alone or in combination with other molecules known to have a beneficial effect on retinal attachment or damaged retinal tissue, including molecules capable of tissue repair and regeneration and/or inhibiting inflammation. Examples of useful, cofactors include anti-VEGF agents (such as an antibody or FAB against VEGF, e.g., Lucentis or Avastin), basic fibroblast growth factor (bFGF), ciliary neurotrophic factor (CNTF), axokine (a mutein of CNTF), leukemia inhibitory factor (LIF), neutrotrophin 3 (NT-3), neurotrophin-4 (NT-4), nerve growth factor (NGF), insulin-like growth factor II, prostaglandin E2, 30 kD survival factor, taurine, and vitamin A. Other useful cofactors include symptom-alleviating cofactors, including antiseptics, antibiotics, antiviral and antifungal agents and analgesics and anesthetics Suitable agents for combination treatment with the compounds of the invention include agents known in the art that are able to modulate the activities of complement components.
A combination therapy regimen may be additive, or it may produce synergistic results (e.g., reductions in complement pathway activity more than expected for the combined use of the two agents). In some embodiments, the present invention provide a combination therapy for preventing and/or treating AMD or another complement related ocular disease as described above with a compound of the invention and an anti-angiogenic, such as anti-VEGF agent (including Lucentis and Avastin) or photodynamic therapy (such as verteporfin).
In some embodiments, the present invention provide a combination therapy for preventing and/or treating autoimmune disease as described above with a compound of the invention and a B-Cell or T-Cell modulating agent (for example cyclosporine or analogs thereof, rapamycin, RAD001 or analogs thereof, and the like). In particular, for multiple sclerosis therapy may include the combination of a compound of the invention and a second MS agent selected from fingolimod, cladribine, tysarbi, laquinimod, rebif, avonex and the like.
In one embodiment, the invention provides a method of modulating activity of the complement alternative pathway in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to the definition of formula (I). The invention further provides methods of modulating the activity of the complement alternative pathway in a subject by modulating the activity of Factor D, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to the definition of Formula (I).
In one embodiment, the invention provides a compound according to the definition of formula (I), (Ia), (VII) or any subformulae thereof, for use as a medicament.
In one embodiment, the invention provides the use of a compound according to the definition of formula (I), (Ia), (VII) or any subformulae thereof, for the treatment of a disorder or disease in a subject mediated by complement activation. In particular, the invention provides the use of a compound according to the definition of formula (I), (Ia), (VII) or any subformulae thereof, for the treatment of a disorder or disease mediated by activation of the complement alternative pathway.
In one embodiment, the invention provides the use of a compound according to the definition of formula (I), (Ia), in the manufacture of a medicament for the treatment of a disorder or disease in a subject characterized by activation of the complement system. More particularly in the manufacture of a medicament for the treatment of a disease or disorder in a subject characterized by over activiation of the complement alternative pathway.
In one embodiment, the invention provides the use of a compound according to the definition of formula (I), (Ia), or subformulae thereof for the treatment of a disorder or disease in a subject characterized by activation of the complement system. More particularly, the invention provides uses of the compounds provided herein in the treatment of a disease or disorder characterized by over activiation of the complement alternative pathway or the C3 amplification loop of the alternative pathway. In certain embodiments, the use is in the treatment of a disease or disorder is selected from retinal diseases (such as age-related macular degeneration).
The present invention provides use of the compounds of the invention for treating a disease or disorder associated with increased complement activity by administering to a subject in need thereof an effective amount of the compounds of Formula (I) of the invention. In certain aspects, uses are provided for the treatment of diseases associated with increased activity of the C3 amplification loop of the complement pathway. In certain embodiments, uses of treating or preventing compelment mediated diseases are provided in which the complement activation is induced by antibody-antigen interactions, by a component of an autoimmune disease, or by ischemic damage.
In a specific embodiment, the present invention provides use of the compounds of the invention for treating or preventing age-related macular degeneration (AMD). In certain embodiments, patients who are currently asymptomatic but are at risk of developing a symptomatic macular degeneration related disorder are suitable for administration with a compound of the invention. The use in treating or preventing AMD include, but are not limited to, uses in treating or preventing one or more symptoms or aspects of AMD selected from formation of ocular drusen, inflammation of the eye or eye tissue, loss of photoreceptor cells, loss of vision (including loss of visual acuity or visual field), neovascularization (including CNV), retinal detachment, photoreceptor degeneration, RPE degeneration, retinal degeneration, chorioretinal degeneration, cone degeneration, retinal dysfunction, retinal damage in response to light exposure, damage of the Bruch's membrane, and/or loss of RPE function.
The compound of Formula (I) of the invention can be used, inter alia, to prevent the onset of AMD, to prevent the progression of early AMD to advanced forms of AMD including neovascular AMD or geographic atrophy, to slow and/or prevent progression of geographic atrophy, to treat or prevent macular edema from AMD or other conditions (such as diabetic retinopathy, uveitis, or post surgical or non-surgical trauma), to prevent or reduce the loss of vision from AMD, and to improve vision lost due to pre-existing early or advanced AMD. It can also be used in combination with anti-VEGF therapies for the treatment of neovascular AMD patients or for the prevention of neovascular AMD. The present invention further provides methods of treating a complement related disease or disorder by administering to a subject in need thereof an effective amount of the compound(s) of the invention, wherein said disease or disorder is selected from uveitis, adult macuar degeneration, diabetic retinopathy, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, imtermediate uveitis, birdshot retino-chorioditis, sympathetic ophthalmia, ocular dicatricial pemphigoid, ocular pemphigus, nonartertic ischemic optic neuropathy, post-operative inflammation, and retinal vein occlusion.
In some embodiments, the present invention provides uses for treating a complement related disease or disorder. Examples of known complement related diseases or disorders include: neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, thermal injury including burns or frostbite, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration and neural regeneration. In addition, other known complement related disease are lung disease and disorders such as dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, inert dusts and minerals (e.g., silicon, coal dust, beryllium, and asbestos), pulmonary fibrosis, organic dust diseases, chemical injury (due to irritant gases and chemicals, e.g., chlorine, phosgene, sulfur dioxide, hydrogen sulfide, nitrogen dioxide, ammonia, and hydrochloric acid), smoke injury, thermal injury (e.g., burn, freeze), asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, uveitis (including Behcet's disease and other sub-types of uveitis), antiphospholipid syndrome.
In a specific embodiment, the present invention provides use of the compounds of the invention for treating a complement related disease or disorder, wherein said disease or disorder is asthma, arthritis (e.g., rheumatoid arthritis), autoimmune heart disease, multiple sclerosis, inflammatory bowel disease, ischemia-reperfusion injuries, Barraquer-Simons Syndrome, hemodialysis, systemic lupus, lupus erythematosus, psoriasis, multiple sclerosis, transplantation, diseases of the central nervous system such as Alzheimer's disease and other neurodegenerative conditions, atypicaly hemolytic uremic syndrome (aHUS), glomerulonephritis (including membrane proliferative glomerulonephritis), blistering cutaneous diseases (including bullous pemphigoid, pemphigus, and epidermolysis bullosa), ocular cicatrical pemphigoid or MPGN II.
In a specific embodiment, the present invention provides use of the compounds of the invention for treating glomerulonephritis. Symptoms of glomerulonephritis include, but not limited to, proteinuria; reduced glomerular filtration rate (GFR); serum electrolyte changes including azotemia (uremia, excessive blood urea nitrogen—BUN) and salt retention, leading to water retention resulting in hypertension and edema; hematuria and abnormal urinary sediments including red cell casts; hypoalbuminemia; hyperlipidemia; and lipiduria. In a specific embodiment, the present invention provides methods of treating paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of a composition comprising an compound of the present invention with or without concomitent administration of a complement C5 inhibitor or C5 convertase inhibitor such as Soliris.
In a specific embodiment, the present invention provides use of the compounds of the invention for reducing the dysfunction of the immune and/or hemostatic systems associated with extracorporeal circulation. The compounds of the present invention can be used in any procedure which involves circulating the patient's blood from a blood vessel of the patient, through a conduit, and back to a blood vessel of the patient, the conduit having a luminal surface comprising a material capable of causing at least one of complement activation, platelet activation, leukocyte activation, or platelet-leukocyte adhesion. Such procedures include, but are not limited to, all forms of ECC, as well as procedures involving the introduction of an artificial or foreign organ, tissue, or vessel into the blood circuit of a patient. More particularly, such procedures include, but are not limited to, transplantation procedures including kidney, liver, lung or heart transplant procedures and islet cell transplant procedures.
The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees centrigrade (° C.). If not mentioned otherwise, all evaporations are performed under reduced pressure, typically between about 15 mm Hg and 100 mm Hg (=20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21). Further, the compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples.
Inter Alia the Following In Vitro Tests May be Used
Human Complement Factor D Assay: Method 1
Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at various concentrations for 1 hour at room temperature in 0.1 M Hepes buffer, pH 7.5, containing 1 mM MgCl2, 1 M NaCl and 0.05% CHAPS. A synthetic substrate Z-Lys-thiobenzyl and 2,4-dinitrobenzenesulfonyl-fluoresceine are added to final concentrations of 200 μM and 25 μM, respectively. The increase in fluorescence is recorded at excitation of 485 nm and emission at 535 nm in a microplate spectrofluorimeter. IC50 values are calculated from percentage of inhibition of complement factor D-activity as a function of test compound concentration.
Human Complement Factor D Assay: Method 2
Recombinant human factor D (expressed in E. coli and purified using standard methods) at a 10 nM concentration is incubated with test compound at various concentrations for 1 hour at room temperature in 0.1 M PBS pH 7.4 containing 7.5 mM MgCl2 and 0.075% (w/v) CHAPS. Cobra venom factor and human complement factor B substrate complex is added to a final concentration of 200 nM. After 1 hour incubation at room temperature, the enzyme reaction was stopped by addition of 0.1 M sodium carbonate buffer pH 9.0 containing 0.15 M NaCl and 40 mM EDTA. The product of the reaction, Ba, was quantified by means of an enzyme-linked-immunosorbent assay. IC50 values are calculated from percentage of inhibition of factor D-activity as a function of test compound concentration.
The following Examples, while representing preferred embodiments of the invention, serve to illustrate the invention without limiting its scope.
ABBREVIATIONS


    AcOH acetic acid
    aq. aqueous
    c-hexane cyclohexane
    DAST diethylaminosulfur trifluoride
    DBU 1,8-Diazabicycloundec-7-ene
    DEAD diethyl azodicarboxylate
    DIPEA N,N-diisopropylethylamine
    DIBALH diisobutylaluminium hydride
    DMAP 4-dimethylaminopyridine
    DME dimethyl ether
    DMF dimethylformamide
    DMSO dimethylsulfoxide
    DPPA diphenylphosphoryl azide
    EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
    Ether/Et2O diethylether
    Et3N triethylamine
    EtOAc ethyl acetate
    EtOH ethanol
    Flow flow rate
    h hour(s)
    HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
    HPLC High Performance Liquid Chromatography
    iPrOH isopropanol
    L liter(s)
    LAH Lithium aluminum hydride
    LC-MS Liquid Chromatography/Mass Spectrometry
    MeI methyl iodide
    MeOH methanol
    MesCl Mesyl Chloride
    min minute(s)
    mL milliliter
    MS Mass Spectrometry
    NaH sodium hydride
    NMR Nuclear Magnetic Resonance
    Pd/C palladium on charcoal
    Prep. Preparative
    Rf retention factor
    RP reverse phase
    RT room temperature
    sat. saturated
    TBAF tetra-butylammonium fluoride
    TFA trifluoroacetic acid
    THF tetrahydrofurane
    TLC Thin Layer Chromatography
    T3P propylphosphonic anhydride
    tr retention time
    UPLC ultra performance liquid chromatography

Trademarks

    Celite=Celite® (The Celite Corporation)=filtering aid based on diatomaceous earth
    Nucleosil=Nucleosil®, trademark of Machery & Nagel, Düren, FRG for HPLC materials
    PL Thiol Cartridge=Stratosphere® SPE, PL-Thiol MP SPE+, 500 mg per 6 mL tube, 1.5 mmol (nominal)


Temperatures are measured in degrees Celsius. Unless otherwise indicated, the reactions were performed RT.
Phase separator: Biotage—Isolute Phase separator (Part Nr: 120-1908-F for 70 mL and Part Nr: 120-1909-J for 150 mL)
TLC conditions: Rf values for TLC are measured on 5×10 cm TLC plates, silica gel F254, Merck, Darmstadt, Germany.
HPLC Conditions:
HPLC were performed using an Agilent 1100 or 1200 series instrument. Mass spectra and LC/MS were determined using an Agilent 1100 series instrument.
a: Waters Symmetry C18, 3.5 μm, 2.1×50 mm, 20-95% CH3CN/H2O/3.5 min, 95% CH3CN/2 min, CH3CN and H2O containing 0.1% TFA, flow: 0.6 mL/min
b: Waters Sunfire C18, 2.5 μm, 3×30 mm, 0-10% in 0.5 min, 10-98% CH3CN in H2O in 2.5 min, 98% CH3CN in H2O for 0.7 min, CH3CN and H2O containing 0.1% TFA, flow: 1.4 mL/min
c: Agilent Eclipse XDB-C18; 1.8 μm; 2.1×30 mm 20-100% CH3CN/H2O/3 min, 100% CH3CN/0.75 min, CH3CN and H2O containing 0.1% of TFA, flow: 0.6 mL/min
d: Agilent Eclipse XDB-C18; 1.8 μm; 2.1×30 mm 5-100% CH3CN/H2O/3 min, 100% CH3CN/0.75 min, CH3CN and H2O containing 0.1% of TFA, flow: 0.6 mL/min
e: Agilent Eclipse XDB-C18, 1.8 μm, 4.6×50 mm, 5-100% CH3CN/H2O/6 min, 100% CH3CN/1.5 min, CH3CN and H2O containing 0.1% TFA, flow: 1 mL/min
f: Waters X-Bridge C18, 2.5 μm, 3×50 mm, 10-98% CH3CN/H2O/8.6 min, 98% CH3CN/H2O/1.4 min, CH3CN and H2O both containing 0.73 mM NH4OH, flow: 1 mL/min, T=30° C.
g. UPLC/MS: Waters Acquity; UPLC column: Waters Acquility HSS T3; 1.8 μm; 2.1×50 mm 2-98% CH3CN/H2O/1.4 min, H2O containing 0.05% HCOOH+3.75 mM NH4OAc and CH3CN containing 0.04% HCOOH, flow: 1.4 mL/min.
h: Waters X-Bridge C18 2.5 μm 3×30 mm, 10-98% CH3CN/H2O/3 min, 98% CH3CN/0.5 min, CH3CN and H2O containing 0.1% of TFA, flow: 1.4 mL/min, T=40° C.
g: Waters XBridge C18, 2.5 μm, 3×50 mm, 10-98% CH3CN/H2O/8.6 min, 98% CH3CN/1.4 min, CH3CN and H2O containing 0.1% TFA, flow: 1.4 mL/min, temperature 40° C.
Part A: Synthesis of Substituted Aromatic or Heteroromatic Building Blocks:




A. 1H-Indole-3-carboxylic acid benzyl ester
To a solution of 1H-indole-3-carboxylic acid (5 g, 31 mmol) in DMF (70 mL) under a nitrogen atmosphere at 0° C. was added cesium carbonate (11 g, 31 mmol) and benzyl bromide (4.05 mL, 34.1 mmol). The reaction mixture was stirred at RT for 48 h and poured into water. EtOAc was added and the layers were separated and the aqueous layer was extracted with EtOAc (×3). The combined organic layers were washed with water, dried over Na2SO4, filtered and concentrated. The residue was taken up in Et2O and the resulting precipitate was filtered-off to give the title compound. TLC, Rf (c-hexane/EtOAc 1:1)=0.55; MS (LC-MS): 252.1 [M+H]+, 274.0 [M+Na]+, 525.1 [2M+Na]+, 250.1 [M−H]−; tR (HPLC conditions a) 3.77 min.
B. 1-Carbamoyl-1H-indole-3-carboxylic acid benzyl ester
To a solution of 1H-indole-3-carboxylic acid benzyl ester (3.5 g, 13.9 mmol) in THF (70 mL) at 5° C., was added NaH (60% in mineral oil, 557 mg, 13.9 mmol). The mixture was stirred at 5° C. for 30 min before slow dropwise addition of chlorosulfonyl isocyanate (2.42 mL, 27.9 mmol) maintaining the temperature between 5° C. and 10° C. The pale yellow solution was further stirred at RT for 3.5 h. Acetic acid (22.5 mL) was added (exothermic), and the resulting solution was stirred at RT for 1.5 h before addition of ice and water (100 mL). The white thick suspension was stirred at RT for 30 min and the precipitate was filtered-off, taken up in MeOH and filtered-off again to afford the desired compound. 1H-NMR (400 MHz, DMSO): δ (ppm) 8.64 (s, 1H), 8.29 (d, 1H), 8.04 (d, 1H), 7.90 (m, 2H), 7.50 (d, 2H), 7.42 (t, 2H), 7.36-7.30 (m, 3H), 5.38 (s, 2H).
C. 1-carbamoyl-1H-indole-3-carboxylic acid
1-Carbamoyl-1H-indole-3-carboxylic acid benzyl ester (1.33 g, 4.52 mmol) was dissolved in a mixture of DMF/THF 1:1 (28 mL), Pd/C (10%, 250 mg) was added and the solution was degassed 3 times replacing air with nitrogen then nitrogen with hydrogen. The reaction mixture was further stirred under a hydrogen atmosphere overnight and the catalyst was removed through a pad of Celite and washed with THF. The solvents were concentrated under high vacuum to give a yellow solid which was taken up in Et2O and filtered-off to afford the title compound. 1H-NMR (400 MHz, DMSO): δ (ppm) 12.6 (m, 1H), 8.54 (bs, 1H), 8.28 (d, 1H), 8.05 (d, 1H), 7.85 (m, 2H), 7.34-7.27 (m, 2H).
D. 3-isocyanato-indole-1-carboxylic acid amide
To a suspension of 1-carbamoyl-1H-indole-3-carboxylic acid (1.31 g, 6.42 mmol) in toluene (30 mL, CH2Cl2 can also be used instead of toluene) under nitrogen was added Et3N (893 μl, 6.42 mmol). After 15 min DPPA (1.54 mL, 6.42 mmol) was added and the reaction mixture was further stirred at RT overnight. The solvent was evaporated, the residue was taken up in CH2Cl2 and the precipitate was filtered-off to give the acyl azide intermediate (565 mg). Toluene (20 mL) was added and the suspension refluxed for 1.5 h under nitrogen atmosphere until disappearance of the acyl azide observed by TLC. Toluene was concentrated under vacuum and the desired isocyanate was directly used in the next step without further purification. 1H-NMR (400 MHz, CDCl3): δ (ppm) 8.18 (d, 1H), 7.61 (d, 1H), 7.44 (t, 1H), 7.35 (t, 1H), 7.23 (s, 1H), 5.39 (bs, 2H).




A. Tert-butyl 2-(3-acetyl-1H-indazol-1-yl)acetate
To a solution of 1-(1H-indazol-3-yl)ethanone [4498-72-0] (2 g, 12.46 mmol) in CH3CN (50 mL) was added K2CO3 (3.97 g, 28.7 mmol) and tert-butyl 2-bromoacetate (2.58 mL, 17.48 mmol). The reaction mixture was stirred at 90° C. overnight. The reaction mixture was filtered, the residue was washed with CH3CN and the filtrate was concentrated under vacuum. The material thus obtained was used directly in the next step without further purification. MS: 275 [M+H]+; tR (HPLC conditions d): 3.78 min.
B. 2-(3-Acetyl-1H-indazol-1-yl)acetic acid
To a solution of tert-butyl 2-(3-acetyl-1H-indazol-1-yl)acetate (4 g, 12.4 mmol) in CH2Cl2 (45 mL) was added TFA (15 mL, 195.0 mmol), and the reaction mixture was stirred at RT overnight. Then was diluted with CH2Cl2 and MeOH, and volatiles were evaporated under reduced pressure to afford the title compound: MS: 219 [M+H]+; tR (HPLC conditions d): 2.78 min.




A. (3-Acetyl-pyrazolo[3,4-c]pyridin-1-yl)-acetic acid tert-butyl ester
To a solution of 1-(1H-pyrazolo[3,4-c]pyridin-3-yl)-ethanone (Sphinx Scientific laboratory LLC, catalog number: PPY-1-CS01) (2.45 g 14.44 mmol) in CH3CN (50 mL) were added potassium carbonate (3.99 g, 28.9 mmol) and tert-butyl bromoacetate (2.34 mL, 15.88 mmol). The reaction mixture was stirred at RT overnight. The crude mixture was poured into water and extracted with EtOAc (×3). The combined organic extracts were dried (Na2SO4), filtered and concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane/EtOAc 1:0 to 0:1) to give the title compound. TLC, Rf (EtOAc)=0.7; MS: 276 [M+H]+; tR (HPLC conditions c): 2.06 min.
B. (3-Acetyl-pyrazolo[3,4-c]pyridin-1-yl)-acetic acid trifluoroacetate
The title compound was prepared from (3-acetyl-pyrazolo[3,4-c]pyridin-1-yl)-acetic acid tert-butyl ester in a similar manner as described in step B Scheme A2 for the preparation of 2-(3-acetyl-1H-indazol-1-yl)acetic acid. MS: 220 [M+H]+; tR (HPLC conditions c): 0.69 min.







A. 5-(Benzyloxy)-N-methoxy-N-methyl-1H-indazole-3-carboxamide
The title compound was prepared in a similar manner as described by F. Crestey et al., Tetrahedron 2007, 63, 419-428. To 5-(benzyloxy)-1H-indazole-3-carboxylic acid [177941-16-1] (3.50 g, 13.1 mmol) in THF (70 mL) was added N,O-dimethylhydroxylamine (1.40 g, 14.4 mmol). The mixture was cooled to 0° C. before the addition of pyridine (2.30 mL, 28.7 mmol). The solution was stirred at 0° C. for 1.5 h, and then at RT for 1 h. Pyridine (2.10 mL, 26.1 mmol) and EDCI (5.00 g, 26.1 mmol) were added and the mixture was stirred at RT overnight. Water was added to the reaction mixture followed by extraction (×3) with CH2Cl2. The combined organics were washed with saturated aqueous NaHCO3 solution, dried (Phase separator) and concentrated to give the title compound. MS (LC/MS): 312.0 [M+H]+, 334.0 [M+Na]+, 645.1 [2M+Na]+, 310.0 [M−H]−; tR (HPLC conditions e): 4.44 min.
B. Tert-butyl 5-(benzyloxy)-3-(methoxy(methyl)carbamoyl)-1H-indazole-1-carboxylate
The title compound was prepared in a similar manner as described by F. Crestey et al., Tetrahedron 2007, 63, 419-428. To a solution of 5-(benzyloxy)-N-methoxy-N-methyl-1H-indazole-3-carboxamide (3.40 g, 10.9 mmol) in CH2Cl2 (70 mL) was added DMAP (0.13 g, 1.09 mmol), Et3N (1.67 mL, 12.0 mmol) and Boc-anhydride (3.80 mL, 16.4 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 1 h and allowed to return to RT overnight. The reaction mixture was diluted with CH2Cl2 and washed with 50 mL of 0.1 M aqueous HCl solution and water. The organic phase was dried (Phase separator) and concentrated to give the title compound. MS (LC/MS): 434.0 [M+Na]+, 845.0 [2M+Na]+; tR (HPLC conditions e): 5.79 min.
C. Tert-butyl 3-acetyl-5-(benzyloxy)-1H-indazole-1-carboxylate and 1-(5-(benzyloxy)-1H-indazol-3-yl)ethanone
The title compound was prepared in a similar manner as described by F. Crestey et al., Tetrahedron 2007, 63, 419-428. To tert-butyl 5-(benzyloxy)-3-(methoxy(methyl)carbamoyl)-1H-indazole-1-carboxylate (4.70 g, 11.4 mmol) in THF (60 mL), cooled to −78° C., was added MeMgBr (3 M solution in Et2O, 22.9 mL, 68.5 mmol). The reaction mixture was stirred at 78° C. for 1 h. A saturated aqueous NH4Cl solution was added to the reaction mixture and temperature was allowed to raise to RT. The mixture was extracted twice with CH2Cl2, the combined organics were dried (Phase separator) and concentrated to give the title mixture which was used without purification in the next step. 1-(5-(Benzyloxy)-1H-indazol-3-yl)ethanone: MS (LC/MS): 267.0 [M+H]+, 289.0 [M+Na]+, 265.1 [M−H]−; tR (HPLC conditions e): 4.72 min. Tert-butyl 3-acetyl-5-(benzyloxy)-1H-indazole-1-carboxylate: MS (LC/MS): 389.0 [M+Na]+, 310.9 [M−tBu]+, 267.1 [M−Boc]+; tR (HPLC conditions e): 6.12 min.
D. 1-(5-(Benzyloxy)-1H-indazol-3-yl)ethanone
To the mixture of tert-butyl 3-acetyl-5-(benzyloxy)-1H-indazole-1-carboxylate and 1-(5-(benzyloxy)-1H-indazol-3-yl)ethanone (3.80 g, 10.4 mmol) in CH2Cl2 (50 mL) was added TFA (7.99 mL, 104 mmol). The reaction mixture was stirred at RT overnight, then was diluted with CH2Cl2 and washed with 100 mL of 2N aqueous NaOH solution. The aqueous layer was extracted twice with CH2Cl2. The combined organic phases were dried (Phase separator) and concentrated to give the title compound. MS (LC/MS): 267.0 [M+H]+, 289.0 [M+Na]+, 265.1 [M−H]−; tR (HPLC conditions e): 4.71 min.
E. Methyl 2-(3-acetyl-5-(benzyloxy)-1H-indazol-1-yl)acetate
To 1-(5-(benzyloxy)-1H-indazol-3-yl)ethanone (3.50 g, 13.1 mmol) in CH3CN (100 mL) was added K2CO3 (4.54 g, 32.9 mmol) and methyl 2-bromoacetate (1.33 mL, 14.5 mmol). The reaction mixture was stirred at 90° C. for 90 min. Then was filtered and the residue was washed with CH3CN. Volatiles were evaporated and the crude mixture was purified by flash column chromatography on silica gel (c-hexane/EtOAc 1:1 to 1:3) to give the title compound. TLC, Rf (c-hexane/EtOAc 1:3)=0.64; MS (LC/MS): 339.0 [M+H]+, 361.0 [M+Na]+; tR (HPLC conditions e): 5.09 min.
F. Methyl 2-(3-acetyl-5-hydroxy-1H-indazol-1-yl)acetate
To methyl 2-(3-acetyl-5-(benzyloxy)-1H-indazol-1-yl)acetate (3.70 g, 10.9 mmol) in THF (80 mL) was added Pd/C (10%, 400 mg). The reaction mixture was stirred at 50° C. overnight under a H2 atmosphere. Then was filtered over a pad of Celite and the residue washed with CH2Cl2. Solvents were removed under reduced pressure to give the title compound. MS (LC/MS): 248.9 [M+H]+, 271.0 [M+Na]+; tR (HPLC conditions e): 3.36 min.
G. Methyl 2-(3-acetyl-5-(pyrimidin-2-ylmethoxy)-1H-indazol-1-yl)acetate
To methyl 2-(3-acetyl-5-hydroxy-1H-indazol-1-yl)acetate (1.80 g, 7.25 mmol) in CH3CN (75 mL) was added 2-(chloromethyl)pyrimidine hydrochloride (1.32 g, 7.98 mmol) and Cs2CO3 (5.91 g, 18.13 mmol). The reaction mixture was stirred at 70° C. for 2 h. The reaction mixture was filtered and washed with CH3CN. The solvent was removed under reduced pressure and the crude residue was purified by flash column chromatography on silica gel (c-hexane/EtOAc 1:1 to 1:3). TLC, Rf (c-hexane/EtOAc 1:3)=0.35; MS (LC/MS): 340.9 [M+H]+, 363.0 [M+Na]+; tR (HPLC conditions e): 3.64 min.
H. 2-(3-Acetyl-5-(pyrimidin-2-ylmethoxy)-1H-indazol-1-yl)acetic acid
To methyl 2-(3-acetyl-5-(pyrimidin-2-ylmethoxy)-1H-indazol-1-yl)acetate (1.93 g, 5.67 mmol) in THF (15 mL) and water (15 mL) was added LiOH.H2O (0.25 g, 5.95 mmol). The reaction mixture was stirred at RT for 1.5 h. Volatiles were evaporated and the residue was freeze-dried overnight to give the title compound as a lithium salt. MS (LC/MS): 327.0 [M+H]+, 325.1 [M+H]+; tR (HPLC conditions e): 3.24 min.




A. Tert-butyl 2-(3-carbamoyl-1H-indazol-1-yl)acetate
To a suspension of 1H-indazole-3-carboxamide [90004-04-9] (2.00 g, 12.4 mmol) and potassium carbonate (4.12 g, 29.8 mmol) in CH3CN (60 mL) was added tert-butyl bromoacetate (2.20 mL, 14.9 mmol) dropwise at RT, and the resulting mixture was refluxed for 16 h. The mixture was then cooled to RT and filtered, the solid was washed with CH3CN and the filtrate was concentrated under vacuum. The residual oil was used directly in the next step without further purification. MS (LC/MS): 276.0 [M+H]+; tR (HPLC conditions d): 3.22 min.
B. (3-Carbamoyl-indazol-1-yl)-acetic acid
To a solution of tert-butyl 2-(3-carbamoyl-1H-indazol-1-yl)acetate (3.42 g, 12.4 mmol) in CH2Cl2 (20 mL) was added TFA (10 mL, 130 mmol) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was concentrated in vacuo, the residual solid was suspended in MeOH and concentrated again in vacuo to give the title compound. MS (UPLC/MS): 220 [M+H]+; tR (HPLC conditions d): 1.79 min.
(3-Carbamoyl-6-chloro-indazol-1-yl)-acetic acid




Was prepared from 6-chloro-1H-indazole-3-carboxamide by using the same procedures as for the preparation of (3-carbamoyl-indazol-1-yl)-acetic acid. MS (UPLC-MS): 254 [M+H]+; tR (HPLC conditions b): 1.43 min.
6-chloro-1H-indazole-3-carboxamide
To a solution of 6-chloro-1H-indazole-3-carboxylic acid (500 mg, 2.54 mmol), ammonium chloride (408 mg, 7.63 mmol) and HBTU (1.45 g, 3.82 mmol) in DMF (10 ml) was added DIPEA (1.33 ml, 7.63 mmol) and the reaction mixture was stirred for 16 h at RT. The reaction mixture was concentrated, diluted in EtOAc, washed with 1N HCl, dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography on silica gel (CH2Cl2/MeOH 1:0 to 8:2). MS (UPLC-MS): 196 [M+H]+; tR (HPLC conditions b): 1.47 min.
(3-Carbamoyl-6-methyl-indazol-1-yl)-acetic acid




Was prepared from 6-methyl-1H-indazole-3-carboxamide by using the same procedures as for the preparation of (3-carbamoyl-indazol-1-yl)-acetic acid. MS (UPLC-MS): 234 [M+H]+; tR (HPLC conditions b): 1.33 min.
6-methyl-1H-indazole-3-carboxamide
To a solution of 6-methyl-1H-indazole-3-carboxylic acid (440 mg, 2.50 mmol), ammonium chloride (401 mg, 7.49 mmol) and HBTU (1.42 g, 3.75 mmol) in DMF (10 ml) was added DIPEA (1.31 ml, 7.49 mmol) and the reaction mixture was stirred for 16 h at RT. The reaction mixture was concentrated, diluted in EtOAc, washed with 1N HCl, dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography on silica gel (CH2Cl2/MeOH 1:0 to 8:2). MS (UPLC-MS): 176 [M+H]+; tR (HPLC conditions b): 1.30 min.




A. 3-Iodo-1H-pyrazolo[3,4-c]pyridine
To a solution of 1H-pyrazolo[3,4-c]pyridine [271-47-6] (4.00 g, 33.6 mmol) in DMF (50 mL) were added iodine (12.8 g, 50.4 mmol) and potassium hydroxide (4.70 g, 84.0 mmol). The reaction mixture was stirred at RT for 16 h. The mixture was diluted with 10% sodium thiosulfate and water, then extracted (3×) with EtOAc. The combined organic extracts were washed with brine, dried (Phase separator) and concentrated under vacuum. MS (LC/MS): 246.0 [M+H]+; tR (HPLC conditions d): 0.48 min.
B. Tert-butyl 2-(3-iodo-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate
To a suspension of 3-iodo-1H-pyrazolo[3,4-c]pyridine (6.24 g, 22.9 mmol) and potassium carbonate (7.29 g, 52.7 mmol) in CH3CN (50 mL) was added tert-butyl bromoacetate (4.06 mL, 27.5 mmol) dropwise at RT and the resulting mixture was heated to reflux for 2 h. The mixture was cooled to RT and filtered, the solid was washed with CH3CN and the filtrate was concentrated under vacuum. The residual oil was purified by flash column chromatography on silica gel (EtOAc/c-hexane 1:4, to 1:2, to 1:1) to give the title compound. MS (LC/MS): 360.0 [M+H]+; tR (HPLC conditions d): 2.93 min.
C. Tert-butyl 2-(3-cyano-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate
A mixture of tert-butyl 2-(3-iodo-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (3.76 g, 10.5 mmol), Zn(CN)2 (1.35 g, 11.5 mmol), Pd(dppf)Cl2 (855 mg, 1.05 mmol), Pd2(dba)3 (959 mg, 1.05 mmol), water (4 mL) and DMF (30 mL) was stirred at 100° C. for 16 h under argon. The reaction mixture was diluted with EtOAc and then was successively washed with water, sat. aq. NaHCO3 (2×) and brine, dried (Phase separator) and concentrated under vacuum. The residual oil was purified by flash column chromatography on silica gel (EtOAc/c-hexane 1:1 then 100% EtOAc). MS (LC/MS): 259.0 [M+H]+; tR (HPLC conditions k): 3.10 min. Further elution of the column with CH2Cl2/MeOH 8:2 and subsequent purification by preparative HPLC (Macherey-Nagel Nucleosil 100-10 C18, 5 μm, 40×250 mm, flow: 40 mL/min, eluent: 5-100% CH3CN/H2O/20 min, 100% CH3CN/2 min, CH3CN and H2O containing 0.1% TFA) afforded tert-butyl 2-(3-carbamoyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate as a side-product. MS (LC/MS): 277.0 [M+H]+; tR (HPLC conditions d): 2.39 min.
D. 2-(3-Carbamoyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid
A solution of tert-butyl 2-(3-cyano-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (663 mg, 2.40 mmol) in TFA (6 mL) was subjected to microwave irradiation at 140° C. for 90 min. The reaction mixture was concentrated in vacuo, the residual solid was suspended in MeOH and volatiles were removed again in vacuo. MS: 221.0 [M+H]+; tR (HPLC conditions d): 0.23 min.
From tert-butyl 2-(3-carbamoyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate
To a solution of tert-butyl 2-(3-carbamoyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (663 mg, 2.40 mmol) in CH2Cl2 (20 mL) was added TFA (10 mL, 130 mmol), and the resulting mixture was stirred at RT for 6 h. The reaction mixture was concentrated in vacuo, the residual solid was suspended in MeOH and volatiles were removed again in vacuo to give the title compound.
(3-Carbamoyl-5-ethyl-pyrazolo[3,4-c]pyridin-1-yl)-acetic acid




was prepared from 5-ethyl-1H-pyrazolo[3,4-c]pyridine by using the same procedures as for the preparation of 2-(3-carbamoyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid. MS (LC-MS): 249 [M+H]+; tR (HPLC conditions d): 0.49 min.

5-Ethyl-1H-pyrazolo[3,4-c]pyridine
Triethylaluminum (21.7 mL, 40.4 mmol, 25 wt % solution in toluene) was added to a vigorously stirred solution of 5-bromo-1H-pyrazolo[3,4-c]pyridine [929617-35-6] (4.00 g, 20.2 mmol) and Pd(PPh3)4 (1.17 g, 1.01 mmol) in THF (100 mL) under argon. The reaction mixture was stirred at 65° C. for 60 h. The mixture was cooled to RT and poured into sat. aq. NH4Cl. The resulting suspension was filtered, the solid was washed with water and discarded. The filtrate and combined washings were extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried (Phase separator) and concentrated under reduced pressure. The residual oil was purified by flash column chromatography on silica gel (EtOAc/c-hexane 50:50, then 75:25, then 100:0) to give the title compound. TLC, Rf (c-hexane/EtOAc 1:3)=0.22; MS (LC-MS): 148 [M+H]+; tR (HPLC conditions d): 0.71 min.
(3-Carbamoyl-7-methyl-pyrazolo[3,4-c]pyridin-1-yl)-acetic acid




was prepared using the same procedure as for the preparation of 2-(3-carbamoyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid starting from 7-methyl-1H-pyrazolo[3,4-c]pyridine. MS (LC-MS): 235 [M+H]+; tR (HPLC conditions d): 0.6 min.

7-Methyl-1H-pyrazolo[3,4-c]pyridine
Trimethylaluminum (23.9 mL, 47.8 mmol, 2M in toluene) was added to a vigorously stirred solution of 7-chloro-1H-pyrazolo[3,4-c]pyridine (3.67 g, 23.9 mmol) and Pd(PPh3)4 (1.38 g, 1.19 mmol) in THF (109 mL) under argon. The reaction mixture was stirred at 65° C. for 16 h. The mixture was cooled to RT and poured into sat. aq. NH4Cl. The resulting suspension was filtered, the solid washed with water and discarded. The filtrate and the combined washings were extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried (Phase separator) and concentrated under reduced pressure to give 7-methyl-1H-pyrazolo[3,4-c]pyridine as a solid. MS (LC-MS): 134 [M+H]+; tR (HPLC conditions d): 0.25 min.
7-Chloro-1H-pyrazolo[3,4-c]pyridine
A solution of 2-chloro-4-methylpyridin-3-amine [133627-45-9] (3.0 g, 21.0 mmol) in acetic acid (300 mL) was treated with a solution of sodium nitrite (1.45 g, 21.0 mmol) in water (2.5 mL). The reaction mixture was stirred at RT for 15 min then allowed to stand at RT for 24 h. An additional solution of sodium nitrite (500 mg, 7.25 mmol) in water (1 mL) was added to the mixture which was allowed to stand at RT for 3 h. Acetic acid was evaporated under reduced pressure and the residual aqueous solution was partitioned between EtOAc and sat. aq. NaHCO3. The insoluble solid was filtered off (dried under vacuum; batch 1) and the organic filtrate was washed with water and brine, dried (Phase separator) and concentrated under vacuum (batch 2). The two batches were combined to give 7-chloro-1H-pyrazolo[3,4-c]pyridine as a solid. MS (LC-MS): 153 [M+H]+, tR (HPLC conditions d): 0.9 min.
(3-Carbamoyl-5,7-di methyl-pyrazolo[3,4-c]pyridin-1-yl)-acetic acid




was prepared from 5,7-dimethyl-1H-pyrazolo[3,4-c]pyridine by using the same procedures as described for the preparation of 2-(3-carbamoyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid. MS (LC-MS): 249 [M+H]+, tR (HPLC conditions e): 0.9 min.

5,7-Dimethyl-1H-pyrazolo[3,4-c]pyridine
To a vigorously stirred solution of 7-bromo-5-methyl-1H-pyrazolo[3,4-c]pyridine (3.65 g, 14.6 mmol) and Pd(PPh3)4 (845 mg, 0.73 mmol) in THF (65 mL) was added trimethylaluminum (14.6 mL, 29.3 mmol; 2 M in toluene) under argon. The reaction mixture was stirred at 65° C. for 60 h, then was cooled to RT and poured into a sat. aq. NH4Cl solution. The resulting suspension was filtered, the solid was washed with water and discarded. The filtrate and the combined washings were extracted with EtOAc (3×). The combined organics were washed with brine, dried (Phase separator) and concentrated under reduced pressure to give 5,7-dimethyl-1H-pyrazolo[3,4-c]pyridine as a solid. MS (LC-MS): 148 [M+H]+, tR (HPLC conditions d): 0.50 min.
7-Bromo-5-methyl-1H-pyrazolo[3,4-c]pyridine
A solution of 2-bromo-4,6-dimethylpyridin-3-amine [104829-98-3] (4.00 g, 19.9 mmol) in acetic acid (300 mL) was treated with a solution of sodium nitrite (1.37 g, 19.9 mmol) in water (2.5 mL). The reaction mixture was stirred at RT for 15 min and was then allowed to stand at RT for 24 h. An additional solution of sodium nitrite (500 mg, 7.25 mmol) in water (1 mL) was added to the mixture which was allowed to stand at RT for 16 h. Acetic acid was concentrated under reduced pressure and the residual aqueous solution was partitioned between EtOAc and sat. aq. NaHCO3. The precipitate was filtered off, washed and discarded. The combined filtrates were washed with water and brine, then dried (Phase separator) and concentrated under vacuum to give 7-bromo-5-methyl-1H-pyrazolo[3,4-c]pyridine as a solid. MS (LC-MS): 212 [M+H]+, tR (HPLC conditions d): 2.49 min.




A. 3-Iodo-5-methyl-1H-pyrazolo[3,4-c]pyridine
To a solution of 5-methyl-1H-pyrazolo[3,4-c]pyridine [76006-06-9] (1.00 g, 7.51 mmol) in DMF (15 mL) were added iodine (2.86 g, 11.3 mmol) and potassium hydroxide (1.05 g, 18.8 mmol). The reaction mixture was stirred at RT for 60 h. The mixture was diluted with 10% sodium thiosulfate and water, the resulting suspension was filtered. The solid was washed with water and dried under vacuum. MS (LC/MS): 260.0 [M+H]+; tR (HPLC conditions d): 0.28 min.
B. Tert-butyl 2-(3-Iodo-5-methyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate
To a suspension of 3-iodo-5-methyl-1H-pyrazolo[3,4-c]pyridine (1.00 g, 3.86 mmol), and potassium carbonate (1.28 g, 9.26 mmol) in CH3CN (40 mL) was added tert-butyl bromoacetate (0.685 mL, 4.63 mmol) dropwise at RT and the resulting mixture was refluxed for 16 h. The mixture was cooled to RT and filtered, the solid was washed with CH3CN and the filtrate was concentrated under vacuum. The residual oil was used directly in the next step without further purification. MS (LC/MS): 374.0 [M+H]+; tR (HPLC conditions d): 2.96 min.
C. Tert-butyl 2-(3-cyano-5-methyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate
A mixture of tert-butyl 2-(3-iodo-5-methyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (1.00 g, 2.55 mmol), Zn(CN)2 (329 mg, 2.55 mmol), Pd(dppf)Cl2 (208 mg, 0.25 mmol), Pd2(dba)3 (233 mg, 0.25 mmol), water (2.7 mL) and DMF (20 mL) was subjected to microwave irradiation at 120° C. for 30 min under argon. The reaction mixture was filtered through a pad of Celite and the filtrate was diluted with water and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were washed with brine, dried (Phase separator) and concentrated under vacuum. The residual oil was purified by flash chromatography on silica gel (EtOAc/c-hexane 1:2 then 1:1) to give the title compound. MS (LC/MS): 273.0 [M+H]+; tR (HPLC conditions d): 3.04 min.
D. (3-Carbamoyl-5-methyl-pyrazolo[3,4-c]pyridin-1-yl)-acetic acid
A solution of tert-butyl 2-(3-cyano-5-methyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (250 mg, 0.92 mmol) in TFA (4 mL) was subjected to microwave irradiation at 140° C. for 90 min. The reaction mixture was concentrated in vacuo, the residual solid was suspended in MeOH and concentrated again in vacuo. MS: 235.0 [M+H]+; tR (HPLC conditions d): 0.24 min.
Part B: Synthesis of Substituted Proline Building Blocks:







A. (S)-2,5-Dihydro-pyrrole-1,2-dicarboxylic acid 1-benzyl ester
To a solution of (S)-2,5-dihydro-1H-pyrrole-2-carboxylic acid (15 g, 133 mmol) and sodium hydroxide (10.6 g, 265 mmol) in THF (150 mL) cooled at 0° C. was added benzylchloroformate (32.0 mL, 166 mmol). The mixture was allowed to reach RT overnight. The reaction mixture was concentrated, water was added and the aqueous layer was extracted with Et2O (2×200 mL), acidified (6N HCl) and extracted with AcOEt (2×200 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated. The crude residue was used in the next step without purification. MS (UPLC/MS): 248 [M+H]+; tR (HPLC conditions b): 1.66 min.
B. (S)-2,5-Dihydro-pyrrole-1,2-dicarboxylic acid dibenzyl ester
To a solution of (S)-2,5-dihydro-pyrrole-1,2-dicarboxylic acid 1-benzyl ester (29.6 g, 120 mmol) in DMF (250 mL) were added cesium carbonate (42.9 g, 132 mmol) followed by benzyl bromide (17.09 mL, 144 mmol) and sodium iodide (2.15 g, 14.37 mmol) and the mixture was stirred at RT for 48 h. The reaction mixture was quenched with water (500 mL) and extracted with EtOAc (3×200 mL). The organic extracts were combined and washed with brine, dried (Na2SO4), filtered and concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane/EtOAc 4:1) to give the desired material. MS (UPLC/MS): 338 [MH−Boc]+; tR (HPLC conditions b): 2.31 min.
C. (1S,2S,5R)-6-Oxa-3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid dibenzyl ester and (1R,2S,5S)-6-Oxa-3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid dibenzyl ester
Were prepared according to the procedure described in Tetrahedron, 1998, 54, 981-986 from (S)-2,5-dihydro-pyrrole-1,2-dicarboxylic acid dibenzyl ester. To a solution of (S)-2,5-dihydro-pyrrole-1,2-dicarboxylic acid dibenzyl ester (7.5 g, 22.23 mmol) in DCE (80 mL) were added mCPBA (7.67 g, 44.5 mmol) and 4,4′-thiobis(6-tert-butyl-m-cresol) (0.797 g, 2.22 mmol). The reaction mixture was then heated to 90° C. overnight. Then was concentrated. The crude residue was diluted in CH2Cl2 (200 mL) and washed with an aq. solution of Na2S2O5 5% and with a sat. aq. solution of NaHCO3. The organic layer was dried (Na2SO4), filtered and concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane/EtOAc 10:0 to 8:2) give (1S,2S,5S)-6-oxa-3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid dibenzyl ester: MS (UPLC/MS): 354 [M+H]+, tR (HPLC conditions b): 2.24 min and (1S,2S,5R)-6-oxa-3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid dibenzyl ester: MS (UPLC/MS): 354 [M+H]+, tR (HPLC conditions b): 2.15 min.
D. (2S,3S,4S)-4-Hydroxy-3-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester and (2S,3R,4R)-3-hydroxy-4-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester
To a solution of (1R,2S,5S)-6-oxa-3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid dibenzyl ester (30 g, 85 mmol) in MeOH (150 mL) was added Amberlyst 15 (30 g). The reaction mixture was heated overnight at 65° C., then allowed to cool to RT and filtered. Amberlyst 15 residue was washed with MeOH. The combined filtrates were concentrated and the crude residue was purified by flash column chromatography on silica gel (c-hexane 100% to EtOAc 100%) to give a mixture of the 2 regioisomers as a yellow oil. Rf, TLC (c-hexane/EtOAc 1:1)=0.5; MS (UPLC/MS): 386.2 [M+H]+, 430.2 [M+HCOO]−; tR (HPLC conditions a): 1.93 min.
E. (2S,3S,4S)-4-Fluoro-3-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester and (2R,3R,4R)-3-fluoro-4-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester
A solution of (2S,3S,4S)-4-hydroxy-3-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester and (2S,3R,4R)-3-hydroxy-4-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester (17.8 g, 46.2 mmol) in CH2Cl2 (250 mL) was cooled under Argon at −78° C. and DAST (12.2 mL, 92 mmol) was added dropwise. The reaction mixture was allowed to reach RT and further stirred for 16 h. The reaction mixture was diluted with CH2Cl2 and carefully quenched with a sat. aq. solution of NaHCO3. The layers were separated, the aqueous layer extracted twice with CH2Cl2, the combined organic extracts were dried over Na2SO4, filtered and concentrated. Purification by flash column chromatography on silica gel (c-hexane/EtOAc 10:0 to 0:10) gave a mixture of the 2 regioisomers as a yellow solid. Rf, TLC (EtOAc)=0.5; MS (UPLC/MS): 388.3 [M+H]+, 405.3 [M+NH4]+; tR (HPLC conditions b): 2.15 min.
F. (2S,3S,4S)-4-Fluoro-3-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester and (2R,3R,4R)-3-Fluoro-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
To a solution of (2S,3S,4S)-4-fluoro-3-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester and (2R,3R,4R)-3-fluoro-4-methoxy-pyrrolidine-1,2-dicarboxylic acid dibenzyl ester (13.6 g, 35.1 mmol) in MeOH (110 mL) was added Pd/C 10% (1.3 g). The reaction was placed under hydrogen atmosphere (by degassing 3 times replacing air with nitrogen then nitrogen with hydrogen) and was stirred for 16 h. The mixture was placed under a nitrogen atmosphere and the catalyst was removed through a pad of Celite and washed with MeOH. After concentration, the residue was dissolved in a mixture of THF (110 mL) and water (55 mL) then aq. 1N NaOH (70.2 mL) and Boc anhydride (16.3 mL, 70.2 mmol) were added and the reaction mixture was stirred at RT for 72 h. After concentration, the crude residue was dissolved in water and extracted twice with Et2O. The aqueous layer was acidified to pH=1 by addition of HCl 2N and extracted twice with EtOAc. The combined organic extracts were dried (Na2SO4), filtered and concentrated to give the desired mixture of regioisomers which was used without further purification in the next step. Rf, TLC (EtOAc)=0.1; MS (UPLC/MS): 264 [M+H]+.
G. (2S,3S,4S)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-3-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester
To a solution of (2S,3S,4S)-4-fluoro-3-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester and (2R,3R,4R)-3-fluoro-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.76 mmol), 2-fluoro-3-methyl-but-2-enylamine hydrochloride (179 mg, 0.84 mmol) and T3P (50% in EtOAc, 0.671 mL, 1.14 mmol) in CH2Cl2 (10 mL) was added DIPEA (0.398 mL, 2.28 mmol). The reaction mixture was stirred 1 h at RT and concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane to c-hexane/EtOAc 1:1) to give (2S,3S,4S)-4-fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-3-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester: MS (UPLC/MS): 349 [M+H]+; tR (HPLC conditions b): 1.75 min.




A. (S)-4-Formyl-2,3-dihydro-pyrrole-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester
POCl3 (7.59 mL, 83 mmol) was added in 25 min at 0° C. under N2 atmosphere to DMF (6.39 mL, 83 mmol) and the mixture was stirred at RT for 20 min. Dry CH2Cl2 (150 mL) was added at 0° C., followed by a solution of (S)-2,3-dihydro-pyrrole-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (10 g, 41.4 mmol) in CH2Cl2 (50 mL). The mixture was stirred 30 min at RT until completion. Then slowly poured into an ice cold aqueous solution of NaOH 10 N (150 mL) and extracted with CH2Cl2 (×3). The combined organic extracts were washed with brine (×2), with water, dried (Na2SO4), filtered and concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane to c-hexane/EtOAc 9:1) to give the desired material as a yellow oil. Rf, TLC (c-hexane/EtOAc 4:1)=0.2; MS (UPLC-MS): 270 [M+H]+, 170 [M−Boc]−; tR (HPLC conditions b): 1.93 min.
B. (S)-4-Hydroxymethyl-2,3-dihydro-pyrrole-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester
A solution of (S)-4-formyl-2,3-dihydro-pyrrole-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (3.32 g, 12.3 mmol) in CH2Cl2 (51.4 mL) was cooled at −78° C. under a nitrogen atmosphere, solid NaBH4 (1 g, 24.7 mmol) was added portionwise maintaining the temperature at −78° C. MeOH (25.7 mL) was added dropwise and the reaction mixture was allowed to reach 0° C. and was stirred 1 h30 at 0° C. The reaction mixture was quenched with an aq. sat. solution of NH4Cl and extracted with CH2Cl2 (×3). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane to c-hexane/EtOAc 1:1 to EtOAc) to give the desired material as a yellow oil. Rf, TLC (c-hexane/EtOAc 1:1)=0.30; MS (UPLC-MS): 272.2 [M+H]+, 316 [M+HCOO]−; tR (HPLC conditions b): 1.74 min.
C. (1R,3S,5S) and (1S,3S,5R)-5-Hydroxymethyl-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-tert-butyl ester 3-ethyl ester
To a solution of (S)-4-hydroxymethyl-2,3-dihydro-pyrrole-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (1.12 g, 4.13 mmol) in CH2Cl2 (115 mL) under argon at −20° C. were slowly added diethylzinc (1M in hexanes, 8.26 mL, 8.26 mmol) and diiodomethane (0.73 mL, 9.08 mmol) and the reaction mixture was further stirred at −10° C. for 2 h. Diethylzinc (1M in hexanes, 8.26 mL, 8.26 mmol) and diiodomethane (0.73 mL, 9.08 mmol) were again added and the reaction mixture was further stirred at −10° C. for 2 h to complete the reaction. A sat. aq. solution of NH4Cl was added slowly (exothermic) at −20° C. followed by CH2Cl2. The layers were separated and the aqueous layer was extracted with CH2Cl2 (×2). To the combined organic layers were added few crystals of Na2S and water (ratio CH2Cl2/H2O 20:1) and the biphasic mixture was stirred for 30 min. Water was added, the layers were separated, dried (Na2SO4), filtered and concentrated to give a mixture of diastereoisomers. The crude residue was purified by flash column chromatography on silica gel (c-hexane/EtOAc 1:1) to give a mixture of diastereoisomers (4:6 (1R,3S,5S)/(1S,3S,5R)). The two diastereoisomers were separated by preparative chiral HPLC (column: 8 SMB columns Chiralpak AD, 20 um, 250×30 mm; eluent: heptane-EtOH 80:20) to give (1R,3S,5S)-5-hydroxymethyl-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-tert-butyl ester 3-ethyl ester: tR (Chiralpak AD-prep, 20 uM, 250×4.6 mm, n-heptane/EtOH 80/20, flow rate 1 mL/min, detection: UV at 210 nm): 6.94 min and (1S,3S,5R)-5-hydroxymethyl-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-tert-butyl ester 3-ethyl ester: tR (Chiralpak AD-prep, 20 uM, 250×4.6 mm, n-heptane/EtOH 80/20, flow rate 1 mL/min, detection: UV at 210 nm): 4.20 min.
D. (1R,3S,5S)-5-Hydroxymethyl-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-tert-butyl ester
To (1R,3S,5S)-5-hydroxymethyl-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-tert-butyl ester 3-ethyl ester (100 mg, 0.31 mmol) in THF (1.5 mL) and H2O (0.15 mL) at 0° C. was added NaOH (1 M in water, 0.63 mL, 0.63 mmol). The solution was stirred 1 h at RT and poured into 10% KHSO4 (until pH 1), EtOAc was added and the layers were separated (×3). The combined organic layers were dried (Na2SO4), filtered and concentrated. The crude residue was used without further purification in the next step. MS (HPLC/MS): 256.2 [M−H]−, 258.3 [M+H]+, 280.3 [M+Na]+, 200.2 [MH−tBu]+, 515.5 [2M+H]+, 537.4 [2M+Na]+; tR (HPLC conditions b): 1.28 min; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.5 (m, 1H), 4.71 (m, 1H), 3.92 (m, 1H), 3.42-3.35 (m, 2H), 3.17 (m, 1H), 2.31 (m, 1H), 2.08 (m, 1H), 1.41 and 1.33 (2 s, 9H), 0.79 (m, 1H), 0.67 (m, 1H).
Part C: Synthesis of Substituted Alkyl Amine Building Blocks:




A. 2-Fluoro-3-methyl-but-2-enoic acid ethyl ester
To a solution of sodium hydride (2.72 g, 68.1 mmol) in DME (35 mL) at 0° C. was added ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate (15 g, 61.9 mmol) dropwise. The mixture was stirred for 1 hr at 20° C. Acetone (6.82 ml, 93 mmol) was then added and the reaction mixture was stirred for 16 h at 90° C. The mixture was diluted with Et2O, washed with water, dried over Na2SO4, filtered and concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane to c-hexane/EtOAc 9:1) to give the title compound. tR (HPLC conditions b): 1.81 min. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 4.20 (q, 2H), 2.06 (d, 3H), 1.83 (d, 3H), 1.24 (t, 3H).
B. 2-Fluoro-3-methyl-but-2-en-1-ol
To a solution of LAH in Et2O (4M, 7.90 mL, 31.6 mmol) at 20° C. was added 2-fluoro-3-methyl-but-2-enoic acid ethyl ester (4.2 g, 28.7 mmol) in Et2O (100 mL) dropwise. The reaction mixture was stirred for 30 min at 20° C. and quenched with saturated aqueous ammonium chloride. The mixture was extracted with Et2O, washed with water and brine, dried over Na2SO4, filtered and concentrated. The crude product was used in the next step without further purification. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 4.94 (m, 1H), 4.04 (d, 1H), 3.98 (d, 1H), 1.62 (d, 3H), 1.59 (d, 3H).
C. 2-(2-Fluoro-3-methyl-but-2-enyl)-isoindole-1,3-dione
To a solution of 2-fluoro-3-methyl-but-2-en-1-ol (2.7 g, 25.9 mmol), phthalimide (4.58 g, 31.1 mmol) and PPh3 (10.20 g, 38.9 mmol) in THF (60 ml) at 20° C. was added DEAD (16.42 ml, 41.5 mmol) and the reaction mixture was stirred for 16 h at 20° C. The reaction mixture was concentrated. The crude residue was purified by flash column chromatography on silica gel (c-hexane to c-hexane/EtOAc 7:3) to give the title compound. tR (HPLC conditions b): 1.81 min. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.91-7.83 (m, 4H), 4.41 (d, 2H), 1.79 (d, 3H), 1.60 (t, 3H).
D. 2-Fluoro-3-methyl-but-2-enylamine hydrochoride
To a solution of 2-(2-fluoro-3-methyl-but-2-enyl)-isoindole-1,3-dione (2.1 g, 7.92 mmol) in EtOH (30 ml) at 20° C. was added hydrazine (0.408 ml, 8.32 mmol) and the reaction mixture was stirred for 16 h at 20° C. The mixture was filtered and 4N HCl in Dioxane was added to the filtrate which was concentrated and dried under high vacuum. The crude product was used in the next step without further purification. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 3.76-3.63 (m, 2H), 1.68 (d, 3H), 1.65 (d, 3H).
2-Fluoro-3-Di-(trideutero-methyl)-allylamine hydrochloride




The title compound was prepared from hexadeuterated acetone by using the same procedure as described for the preparation of 2-fluoro-3-methyl-but-2-enylamine hydrochoride. tR (HPLC conditions g): 0.42 min.
2-Cyclopentylidene-2-fluoro-ethylamine hydrochloride




The title compound was prepared from cyclopentanone by using the same procedure as described for the preparation of 2-fluoro-3-methyl-but-2-enylamine hydrochoride. MS (HPLC/MS): 130 [M+H]+; tR (g): 0.42 min.




A. 2-Fluoro-3-methyl-but-2-enoic acid
To a solution of ethyl 2-fluoro-3-methylbut-2-enoate (2.68 g, 18.34 mmol) in THF (40 mL)/MeOH (20 mL)/Water (20 mL) was added LiOH*H2O (0.769 g, 18.34 mmol) at RT. The reaction mixture was stirred for 60 h and was partially concentrated under reduced pressure. The remaining reaction mixture was acidified to pH 1 by addition of 1N HCl and subsequently extracted with CH2Cl2 (×3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to afford the title compound which was used in the next step without further purification. MS (UPLC/MS): 117 [M−H]−; tR (HPLC conditions g): 0.53 min.
B. 2-Fluoro-3-methyl-but-2-enoic acid methoxy-methyl-amide
To a solution of 2-fluoro-3-methylbut-2-enoic acid (2.11 g, 17.87 mmol) in CH2Cl2 (150 mL) were added successively N,O-dimethylhydroxylamine (1.20 g, 19.65 mmol), EDC*HCl (3.77 g, 19.65 mmol) and HOBT (1.368 g, 8.93 mmol) at RT. The reaction mixture was cooled to 0° C., N-methylmorpholine (5.89 ml, 53.6 mmol) was added and the mixture was stirred for 16 h at RT. The reaction mixture was quenched with water and successively extracted with citric acid (0.5 M aq. solution), NaHCO3 (5% aq. solution) and brine. The organic layer was dried over Na2SO4, filtered and concentrated to give the title compound which was used in the next step without further purification. MS (UPLC/MS): 162 [M+H]+; tR (HPLC conditions g): 0.69 min.
C. 3-Fluoro-4-methyl-pent-3-en-2-one
To a solution of 2-fluoro-3-methyl-but-2-enoic acid methoxy-methyl-amide (1 g, 6.2 mmol) in Et2O (50 mL) was added dropwise methylmagnesium bromide (3M in Et2O, 4.14 ml, 12.41 mmol) at RT and under an argon atmosphere. The suspension was stirred 1 h at RT. The reaction mixture was quenched with water at 0° C. and the layers were separated. The aqueous layer was extracted with Et2O (×2). The combined organic layers were dried (phase separator) and the resulting solution used in the next step without further purification. tR (HPLC conditions g): 0.82 min.
D. (R,S)-3-Fluoro-4-methyl-pent-3-en-2-ol (racemic)
To a solution of 3-fluoro-4-methylpent-3-en-2-one (721 mg, 6.21 mmol) in Et2O (50 mL) under a nitrogen atmosphere was added dropwise LiBH4 (2M in THF, 0.776 mL, 1.55 mmol) at 0° C. The reaction mixture was allowed to reach RT and stirred for 1 h. Additional LiBH4 (2M in THF, 0.776 mL, 1.552 mmol) was added dropwise at RT and the reaction mixture was stirred for 3 h. Then cooled with an icebath and water (10 mL) was added. The layer were extracted and the organic layer was dried (phase separator). The solvents were removed by distillation under normal pressure and the crude title compound was used in the next step without further purification. tR (HPLC conditions h): 1.09 min.
E. (R,S)-4-Azido-3-fluoro-2-methyl-pent-2-ene (racemic)
To a solution of (R,S)-3-fluoro-4-methyl-pent-3-en-2-ol (734 mg, 6.21 mmol) and DBU (1.592 mL, 10.56 mmol) in CH2Cl2 (15 mL) was added slowly DPPA (2.089 ml, 8.70 mmol) at RT and the reaction mixture was stirred for 16 h. EtOAc was added and the organic layer was washed with a sat. aq. NaHCO3 solution and dried (phase separator). The resulting solution containing the title compound was used in the next step without purification. TLC, Rf (c-hexane/EtOAc 8:2)=0.47.
F. (R—S)-2-Fluoro-1,3-dimethyl-but-2-enylamine hydrochloride (racemic)
To a solution of 4-azido-3-fluoro-2-methylpent-2-ene (889 mg; 6.21 mmol) in CH2Cl2 (300 mL) was added triphenylphosphine polymer bound (1.95 mmol/g, 5.90 g, 31.0 mmol) and water (0.56 mL, 31.0 mmol). The mixture was shaked for 16 h at RT. The reaction mixture was filtered, 1N HCl was added, the layers were separated and the aqueous layer was lyophilized to afford the title compound. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 4.44-4.34 (m, 1H), 1.68 (d, 3H), 1.66 (d, 3H), 1.33 (d, 3H).




A. (Z)-2-(2,4,4,4-tetrafluorobut-2-en-1-yl)isoindoline-1,3-dione
Phthalimid (213 mg, 1.450 mmol) was added to a suspension of NaH (52.2 mg, 2.174 mmol) in THF (10 mL) at 0° C., under nitrogen atmosphere, and the mixture was stirred for 1 h at 0° C. 4-Bromo-1,1,1,3-tetrafluoro-but-2-ene (300 mg, 1.450 mmol) was added at 0° C. and the mixture was stirred at RT overnight, then was refluxed and for 5 hours. The reaction was quenched by addition of water and extracted with EtOAc (×3). The combined organic extracts were dried (Na2SO4), filtered and concentrated. The crude reaction mixture was purified by flash column chromatography on silica gel (c-hexane 100% to c-hexane/EtOAc 75:25) to afford the title compound as a white solid. TLC, Rf (c-hexane/EtOAc 8:2)=0.25. MS (UPLC/MS): 288.3 [M+H]+, 286.9 [M−H]−; tR (HPLC conditions h): 2.06 min.
B. (Z)-2,4,4,4-Tetrafluorobut-2-en-1-amine
To a solution of (Z)-2-(2,4,4,4-tetrafluorobut-2-en-1-yl)isoindoline-1,3-dione (150 mg, 0.55 mmol) in EtOH (2.8 mL) was added hydrazine (0.54 mL, 2.75 mmol) and the reaction mixture was stirred at RT overnight. The reaction mixture was filtered and washed with EtOH. A solution of HCl (1.38 mL, 5.49 mmol) in dioxane was added to the filtrate and the resulting solution was concentrated to afford the title compound as a crude hydrochloride salt (beige solid), which was used without purification in the next step.
C. (1R,3S,5R)-tert-butyl 3-(((Z)-2,4,4,4-tetrafluorobut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate
1-Methylimidazole (142 μl, 1.80 mmol) was added to a stirred ice-cooled solution of (1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-tert-butyl ester (194 mg, 0.855 mmol) in CH2Cl2 (2 mL) under nitrogen, and the mixture was stirred for 10 min. Methanesulfonyl chloride (73.3 μl, 0.941 mmol) was added and the mixture was stirred at 0° C. for 30 min, then (Z)-2,4,4,4-tetrafluorobut-2-en-1-amine hydrochloride salt (0.171 mmol) was added and the mixture was further stirred at RT overnight. Water and CH2Cl2 were added, the layers were separated and the aqueous layer was extracted twice with CH2Cl2. The combined organic extracts were washed with brine, dried with (Na2SO4), filtered and concentrated. The crude reaction mixture was purified by preparative HPLC (Waters XBridge C18-OBD, 5 μm, 30×100 mm, eluent: 20% to 100% CH3CN in H2O in 25 min, CH3CN and H2O containing 0.1% NH3 (25% in water), flow: 40 mL/min) to afford the title compound as a yellow oil. TLC, Rf (EtOAc)=0.8. MS (UPLC/MS): 353.3 [M+H]+, 351.3 [M−H]−.
Part D: Synthesis of Examples 1 to 23
1H NMR data for selected compounds can be found at the end of Part D.




A. (1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester
To a solution of (1R,3S,5R)-2-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-tert-butyl ester (1.00 g, 4.40 mmol), 2-fluoro-3-methyl-but-2-enylamine hydrochoride (0.965 mg, 4.84 mmol) and T3P (50% in EtOAc, 3.89 mL, 6.60 mmol) in CH2Cl2 (30 mL) under a nitrogen atmosphere was added DIPEA (2.31 mL, 13.2 mmol). The reaction mixture was stirred at RT for 1 h and concentrated. The residual material was purified by flash chromatography on silica gel (c-hexane/AcOEt 1-0 to 1-1). MS (UPLC/MS): 313 [M+H]+; tR (HPLC conditions b): 1.79 min; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.08 (bs, 1H), 3.96-3.76 (m, 3H), 3.30 (m, 1H), 2.20 (m, 1H), 1.97 (m, 1H), 1.65 (d, 3H), 1.58 (d, 3H), 1.53 (m, 1H), 1.33 (m, 9H), 0.70 (m, 1H), 0.34 (m, 1H).
B. (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide trifluoroacetate
To a solution of (1R,3S,5R)-3-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester (170 mg, 0.54 mmol) in CH2Cl2 (5 mL) was added TFA (0.419 mL, 5.44 mmol) and the solution was stirred at RT for 16 h. The crude reaction mixture was concentrated under vacuum and was used without further purification in the next step. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.71 (bs, 1H), 9.05 (bs, 1H), 8.75 (t, 1H), 4.09-3.87 (m, 3H), 3.28 (m, 1H), 2.45 (m, 1H), 1.92 (m, 1H), 1.79 (m, 1H), 1.68 (d, 3H), 1.61 (d, 3H), 0.88 (m, 1H), 0.77 (m, 1H).
C. Example 1
6-Chloro-1-{2-[(1R,3S,5R)-3-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide
To a solution of (3-carbamoyl-6-chloro-indazol-1-yl)-acetic acid (prepared as described in part A, 41.0 mg, 0.162 mmol), (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide trifluoroacetate (80 mg, 0.147 mmol) and T3P (50% in EtOAc, 0.130 mL, 0.221 mmol) in CH2Cl2 (0.5 mL) under nitrogen atmosphere was added DIPEA (0.077 ml, 0.441 mmol). The reaction mixture was stirred at RT for 1 h and concentrated in vacuo. The residual material was purified by preparative HPLC (Waters Sunfire C18-ODB, 5 μm, 30×100 mm, eluent: 5% to 100% CH3CN in H2O in 25 min, CH3CN and H2O containing 0.1% TFA, flow: 40 mL/min). The residue was further purified by preparative HPLC (X-Bridge C18 ODB 30×100 mm, 5 μm, eluent: 5 to 99% ACN in 12.5 min, then 99% for 2.5 min, 7.3 mM NH3, flow 45 mL/min) to give the title compound. MS (UPLC/MS): 448 [M+H]+; tR (HPLC conditions b): 1.72 min; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.19-8.10 (m, 2H), 7.87 (s, 1H), 7.75 (bs, 1H), 7.45 (bs, 1H), 7.28 (d, 1H), 5.75 (d, 1H), 5.42 (d, 1H), 4.22 (m, 1H), 3.92-3.80 (m, 2H), 3.65 (m, 1H), 2.20 (m, 1H), 2.08 (m, 1H), 1.83 (m, 1H), 1.62 (s, 3H), 1.57 (s, 3H), 1.01 (m, 1H), 0.74 (m, 1H).
The examples below were prepared according to the general procedure described in Scheme D1 for the preparation of Example 1 from building blocks described in Part A, B and C or commercially available:










TABLE 2








Characterization:





(end-table notes),





MS (LC/MS);


Example
Structure
Name
tR (HPLC conditions)


















2




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 3-methyl-but-2- enylcarbamoyl)-2-aza-bicyclo [3.1.0]hex-2-yl]-2-oxo-thyl}- 1H-indazole-3-carboxylic acid amide
414 [M + H]+; tR (b): 1.48 min.  


 


3




1-{2-[(2S,4R)-4-Fluoro-2-(2- fluoro-3-methyl-but-2- enylcarbamoyl)-pyrrolidin-1- yl]-2-oxo-ethyl}-1H- pyrazolo[3,4-c]pyridine-3- carboxylic acid amide
421 [M + H]+; tR (b): 0.94 min. 


 


4




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 3-methyl-but-2- enylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-6-methyl-1H-indazole- 3-carboxylic acid amide
428 [M + H]+; tR (b): 1.63 min.


 


5




1-{2-[(2S,3S,4S)-4-Fluoro-2- (2-fluoro-3-methyl-but-2- enylcarbamoyl)-3-methoxy- pyrrolidin-1-yl]-2-oxo-ethyl}- 1H-pyrazolo[3,4-c]pyridine-3- carboxylic acid amide
451 [M + H]+; tR (b): 0.97 min.


 


6




1-{2-[(1R,3S,5S)-3-(2-Fluoro- 3-methyl-but-2- enylcarbamoyl)-5- hydroxymethyl-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-1H-indazole-3- carboxylic acid amide
444 [M + H]+; tR (b): 1.32 min.


 


7




1-{2-[(2S,4R)-4-Fluoro-2-(2- fluoro-3-methyl-but-2- enylcarbamoyl)-pyrrolidin-1- yl]-2-oxo-ethyl}-1H-indazole- 3-carboxylic acid amide
420 [M + H]+; tR (b): 1.41 min.


 


8




1-{2-[(2S,3S,4S)-4-Fluoro-2- (2-fluoro-3-methyl-but-2- enylcarbamoyl)-3-methoxy- pyrrolidin-1-yl]-2-oxo-ethyl}- 1H-indazole-3-carboxylic acid amide
450 [M + H]+; tR (b): 1.47 min.


 


9




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 3-methyl-but-2- enylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-5,7-dimethyl-1H- pyrazolo[3,4-c]pyridine-3- carboxylic acid amide
443 [M + H]+; tR (b): 1.33 min.


 


10




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 3-methyl-but-2- enylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-1H-pyrazolo[3,4- c]pyridine-3-carboxylic acid amide
415 [M + H]+, tR (b): 1.16 min.


 


11




(1R,3S,5R)-2-[2-(3-Acetyl- indazol-1-yl)-acetyl]-2-aza- bicyclo[3.1.0]hexane-3- carboxylic acid (2-fluoro-3- methyl-but-2-enyl)-amide
413 [M + H]+, tR (g): 0.96 min.  


 


12




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 3-methyl-but-2- enylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-5-methyl-1H- pyrazolo[3,4-c]pyridine-3- carboxylic acid amide
429 [M + H]+; tR (g): 0.59 min.


 


13




(1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-1-yl)- acetyl]-2-aza- bicyclo[3.1.0]hexane-3- carboxylic acid (2-fluoro-3- methyl-but-2-enyl)-amide
414 [M + H]+; tR (b): 1.48 min.


 


14




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 3-methyl-but-2- enylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-7-methyl-1H- pyrazolo[3,4-c]pyridine-3- carboxylic acid amide
429 [M + H]+; tR (b): 1.26 min.


 


15




5-Ethyl-1-{2-[(1R,3S,5R)-3-(2- fluoro-3-methyl-but-2- enylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-1H-pyrazolo[3,4- c]pyridine-3-carboxylic acid amide
443 [M + H]+; tR (b): 1.36 min.


 


16




(1R,3S,5R)-2-{2-[3-Acetyl-5- (pyrimidin-2-ylmethoxy)- indazol-1-yl]-acetyl}-2-aza- bicyclo[3.1.0]hexane-3- carboxylic acid (2-fluoro-3- methyl-but-2-enyl)-amide
521 [M + H]+; tR (b): 1.65 min.


 


17




1-{2-[(1R,3S,5R)-3-(2- Cyclopentylidene-2-fluoro- ethylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-1H-indazole-3- carboxylic acid amide
440 [M + H]+; tR (f): 3.71 min.


 


18




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 3-di-(trideutero-methyl)- allylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-1H-indazole-3- carboxylic acid amide
420 [M + H]+; tR (f): 2.99 min.


 


19




1-{2-[(1R,3S,5R)-3-(2-Fluoro- 1,3-dimethyl-but-2- enylcarbamoyl)-2-aza- bicyclo[3.1.0]hex-2-yl]-2-oxo- ethyl}-1H-indazole-3- carboxylic acid amide
428 [M + H]+; tR (f): 3.39 min.


 


20




1-(2-oxo-2-((1R,3S,5R)-3- (((Z)-2,4,4,4-tetrafluorobut-2- en-1-yl)carbamoyl)-2- azabicyclo[3.1.0]hexan-2- yl)ethyl)-1H-indazole-3- carboxamide
(1) 454 [M + H]+; tR  (g): 3.14 min.





(1) The title compound was prepared according to the general procedure described in Scheme D1 steps B and C starting from the substituted proline derivative prepared as described in Part C.






Example 21 and 22
1-(2-((1R,3S,5R)-3-((S)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide and 1-(2-((1R,3S,5R)-3-((R)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide




Example 19 (360 mg) was dissolved in EtOH (3 mL) and the two diastereosiomers were separated by preparative chiral HPLC (Chiralpak IC, 375×76.5 mm; eluent: heptane/EtOH 50:50; flow: 100 mL/min, detection: 300 nm). The two separated fractions containing the title compounds were evaporated to dryness, then separately dissolved in CH3CN and water, freeze-dried and lyophilized to afford 1-(2-((1R,3S,5R)-3-((S)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide (first eluting product) as a white powder and 1-(2-((1R,3S,5R)-3-((R)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide (second eluting product) as a white powder. The absolute stereochemistry has been assigned tentatively based on the test results for Example 21 and 22 in the biological assay. 1-(2-((1R,3S,5R)-3-((S)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide: TLC, Rf (CH2Cl2/MeOH 9:1)=0.48. MS (UPLC/MS): 428.3 [M+H]+, 426.3 [M−H]−; tR (HPLC conditions g): 3.13 min; tR (Chiralpak IC 5 μm, 250×4.6 mm, heptane/Ethanol 50:50, flow: 1.0 mL/min, temperature 25° C.): 6.72 min. 1-(2-((1R,3S,5R)-3-((R)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide: TLC, Rf (CH2Cl2/MeOH 9:1)=0.48. MS (UPLC/MS): 428.3 [M+H]+, 426.3 [M−H]−; tR (HPLC conditions g): 3.13 min; tR (Chiralpak IC 5 μm, 250×4.6 mm, heptane/Ethanol 50:50, flow: 1.0 mL/min, temperature 25° C.): 10.22 min.
Example 23
(1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide]3-[(2-fluoro-3-methyl-but-2-enyl)-amide]




To a solution of (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide trifluoroacetate (prepared as described in Scheme D1 steps A and B, 60 mg, 0.184 mmol) and Et3N (38 μL, 0.276 mmol) in THF (3 mL) was added a suspension of 3-isocyanato-indole-1-carboxylic acid amide (37 mg, 0.184 mmol, prepared as described in Part A) in THF (2 mL). The resulting solution was stirred at RT under nitrogen for 1 h, diluted in EtOAc, washed with saturated aqueous sodium bicarbonate, dried over Na2SO4, filtered and concentrated. The crude residue was purified by preparative HPLC (Waters SunFire C18-ODB, 5 μm, 30×100 mm, 5% to 100% CH3CN in H2O in 20 min, CH3CN and H2O containing 0.1% TFA, flow: 40 mL/min) to give the title compound. MS (UPLC/MS): 414 [M+H]+; tR (HPLC conditions b): 1.66 min.
1H NMR data for selected compounds:
Example 4
1H NMR (400 MHz, DMSO-d6): δ (ppm): 8.14 (t, 1H), 8.03 (d, 1H), 7.61 (bs, 1H), 7.40 (s, 1H), 7.33 (bs, 1H), 7.10 (d, 1H), 5.68 (d, 1H), 5.37 (d, 1H), 4.22 (m, 1H), 3.86 (m, 2H), 3.67 (m, 1H), 2.45 (s, 3H), 2.21 (m, 1H), 2.08 (m, 1H), 1.83 (m, 1H), 1.62 (s, 3H), 1.57 (s, 3H), 1.01 (m, 1H), 0.70 (m, 1H).
Example 19
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.17 (d, 1H), 8.01 (d, 1H), 7.70-7.62 (bs, 2H), 7.42 (m, 1H), 7.36 (bs, 1H), 7.27 (t, 1H), 5.73 (d, 1H), 5.43 (d, 1H), 4.75 (m, 1H), 4.22 (m, 1H), 3.69 (m, 1H), 2.19 (m, 1H), 2.05 (m, 1H), 1.83 (m, 1H), 1.60 (m, 6H), 1.15 (m, 3H), 0.98 (m, 1H), 0.70 (m, 1H).
Example 20
1H NMR (400 MHz, DMSO-d6): δ (ppm): 8.48 (t, 1H), 8.19 (d, 1H), 7.65 (bs, 1H), 7.64 (d, 1H), 7.41 (t, 1H), 7.39 (bs, 1H), 7.27 (t, 1H), 5.75 (d, 1H), 5.57 (dq, 1H), 5.49 (d, 1H), 4.22 (m, 1H), 3.97 (m, 2H), 3.73 (m, 1H), 2.30 (m, 1H), 2.13 (m, 1H), 1.88 (m, 1H), 1.0 (m, 1H), 0.73 (m, 1H).
Factor D Inhibition Data Using Method 1 to Determine the IC50s.














Example
IC50 (μM)



















1
0.033



2
0.035



3
0.255



4
0.45



5
0.253



6
0.099



7
0.056



8
0.059



9
0.356



10
0.078



11
0.019



12
0.074



13
0.037



14
0.063



15
0.043



16
0.007



17
0.128



18
0.050



19
0.007



20
0.090



21
1.80



22
0.006



23
0.024

## Claims

1. A compound, or a salt thereof, according to formula (II):



wherein
A is a group selected from:




Z1 is C(R1) or N;
Z2 is C(R2) or N;
Z3 is C(R3) or N, wherein at least one of Z1, Z2 or Z3 is not N;
R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6alkoxy, haloC-C6alkyl, haloC-C6alkoxy C1-C6alkoxycarbonyl, CO2H and C(O)NRARB;
R2 and R3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, NRCRD, cyano, CO2H, CONRARB SO2C1-C6alkyl, and SO2NH2, SO2NRARB, C1-C6alkoxycarbonyl, —C(NRA)NRCRD, C1-C6alkyl, haloC1-C6alkyl, C2-C6alkenyl, C1-C6alkoxy, haloC1-C6alkoxy, C2-C6alkenyloxy, wherein each alkyl, alkenyl, alkoxy and alkenyloxy is unsubstituted or substituted with up to 4 substitutents independently selected from halogen, hydroxy, cyano, tetrazoloe, C1-C4alkoxy, C1-C4haloalkoxy, CO2H, C1-C6alkoxycarbonyl, C(O)NRARB, NRCRD, optionally substituted phenyl, heterocycle having 4 to 7 ring atoms and 1, 2, or 3 ring heteroatoms selected from N, O or S, optionally substituted heteroaryl having 5 or 6 ring atoms and 1 or 2 or 3 ring heteroatoms selected from N, O or S, and wherein optional phenyl and heteroaryl substituents are selected from halogen, hydroxy, C1-C4alkyl, C1-C4alkoxy and CO2H;
R4 is selected from the group consisting of hydrogen, halogen, and C1-C6alkyl;
R5 is C1-C4alkyl, hydroxyC1-C4alkyl, C1-C4alkoxyC1-C4alkyl, haloC1-C4alkyl, amino, methylamino
R6 is hydrogen;
R7 is hydrogen or fluoro;
R8 is hydrogen, methyl or hydroxymethyl;
R9 is hydrogen, halogen, hydroxy or methoxy; or
R6 and R7, taken in combination, form a cyclopropane ring; or
R8 and R9, taken in combination, form a cyclopropane ring;
R10 and R11 are independently selected from hydrogen, halogen, C1-C4alkyl, hydroxyC1-C4alkyl, C1-C4alkoxyC1-C4alkyl and haloC1-C4alkyl; or
R10 and R11 taken together can form a 3 to 6 carbocycle or heterocycle containing 1 heteroatom O or S optionally substituted with 1 or 2 groups independently selected from hydroxyl, halogen C1-C4alkyl and C1-C4alkoxy;
R12 is hydrogen, C1-C4alkyl haloC1-C4alkyl, hydroxylC1-C4alkyl or C1-C4alkoxyC1-C4alkyl;
RA and RB are independently selected from the group consisting of hydrogen, and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, hydroxyC1-C6alkyl, or NRARB, taken in combination, form a heterocycle having 4 to 7 ring atoms and 0 or 1 additional ring N, O or S atoms, which heterocycle is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-C4alkyl, halogen, hydroxy, C1-C4alkoxy; and
RC and RD, are each independently selected from the group consisting of hydrogen and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or hydroxyC1-C6alkyl.

2. The compound of claim 1, or a salt thereof, according to formula (III):

3. The compound of claim 1, or a salt thereof, wherein at least two of Z1, Z2 and Z3 are not N.

4. The compound of claim 1, or a salt thereof, wherein Z3 is CR3;
R1 is hydrogen, halogen or C1-C4alkyl;
R2 and R3 are independently selected from the group consisting of hydrogen, halogen, CO2H, C1-C4alkyl and C1-C4alkoxy; wherein alkoxy is unsubstituted or substituted with optionally substituted heteroaryl having 5 or 6 ring atoms and 1, 2 or 3 ring heteroatoms selected from N, O or S, and wherein the heteroaryl is optionally substituted with 1 or 2 halogen or C1-C4alkyl groups;
R4 is hydrogen; and
R5 is amino or C1-C4alkyl.

5. The compound of claim 1, or a salt thereof, wherein
R6 and R7 taken in combination form a cyclopropane ring;
R8 is hydrogen, methyl or hydroxymethyl; and
R9 is hydrogen.

6. The compound of claim 1 or a salt thereof, wherein
R6 and R7 are hydrogen; and
R8 and R9 taken in combination form a cyclopropane ring.

7. The compound of claim 1, or a salt thereof, wherein
R6 and R8 are hydrogen;
R7 is fluoro; and
R9 is hydrogen or methoxy.

8. The compound of claim 1, or a salt thereof, wherein R10 and R11 are methyl.

9. The compound of claim 1, or a salt thereof, wherein R12 is hydrogen.

10. The compound of claim 1, or a salt thereof, wherein R12 is methyl.

11. The compound of claim 1, or a salt thereof, selected from the group consisting of
6-Chloro-1-{2-[(1R,3S,5R)-3-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-thyl}-1H-indazole-3-carboxylic acid amide;
1-{2-[(2S,4R)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-6-methyl-1H-indazole-3-carboxylic acid amide;
1-{2-[(2S,3S,4S)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-3-methoxy-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
1-{2-[(1R,3S,5S)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-5-hydroxymethyl-2-aza-bicyclo [3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
1-{2-[(2S,4R)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
1-{2-[(2S,3S,4S)-4-Fluoro-2-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-3-methoxy-pyrrolidin-1-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-5,7-dimethyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
(1R,3S,5R)-2-[2-(3-Acetyl-indazol-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide;
1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-5-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
(1R,3S,5R)-2-[2-(3-Acetyl-pyrazolo[3,4-c]pyridin-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide;
1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-7-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
5-Ethyl-1-{2-[(1R,3S,5R)-3-(2-fluoro-3-methyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide;
(1R,3S,5R)-2-{2-[3-Acetyl-5-(pyrimidin-2-ylmethoxy)-indazol-1-yl]-acetyl}-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (2-fluoro-3-methyl-but-2-enyl)-amide;
1-{2-[(1R,3S,5R)-3-(2-Cyclopentylidene-2-fluoro-ethylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide;
1-{2-[(1R,3S,5R)-3-(2-Fluoro-3-di-(trideutero-methyl)-allylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide; and
1-{2-[(1R,3S,5R)-3-(2-Fluoro-1,3-dimethyl-but-2-enylcarbamoyl)-2-aza-bicyclo[3.1.0]hex-2-yl]-2-oxo-ethyl}-1H-indazole-3-carboxylic acid amide.

12. The compound of claim 1, or a salt thereof, selected from the group consisting of
1-(2-oxo-2-((1R,3S,5R)-3-(((Z)-2,4,4,4-tetrafluorobut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)ethyl)-1H-indazole-3-carboxamide;
1-(2-((1R,3S,5R)-3-((S)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide; and
1-(2-((1R,3S,5R)-3-((R)-3-fluoro-4-methylpent-3-en-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide.

13. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and a therapeutically effective amount of a compound of claim 1.